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ABSTRACT:  The variability of symptoms in persons with multiple sclerosis (MS) leads to 
dilemmas in clinical decision-making related to mobility device prescription.  When is a good 
time to consider a switch to wheeled mobility?  What is the best type of wheeled mobility? What 
are the changes one can expect as they transition?  Three studies addressed these questions.  
First, we investigated the characteristics of individuals with MS who are about to transition to 
wheeled mobility.  Seven ambulatory individuals with MS performed the timed 25-foot walk test 
(T25FW), and completed questionnaires measuring quality of life (QoL), self-reported fatigue, 
and participation.  These individuals were not able to ambulate at functional speeds and had 
“sedentary” activity levels.  They also had QoL below that of the general population. Next, we 
investigated changes that accompany a transition in primary means of mobility.  Eleven 
individuals with MS or other chronic conditions leading to a decline in mobility function 
participated.  We collected strength, fatigue, participation and QoL data at baseline, and after 
mobility intervention.  Substantive results revealed that individuals may not experience the 
expected declines in strength and endurance as they transition.  Furthermore, they experienced 
improvements in QoL concomitant with amount of daily device use.  Methodological results 
revealed difficulties in conducting longitudinal mobility studies, and addressed research design 
barriers.  Finally, we investigated whether a difference exists in the type of wheeled mobility 
issued to veterans with MS when compared to veterans with a spinal cord injury (SCI).  Using 
 iv
the National Prosthetic Patient Database, we isolated all veterans with MS or an SCI who 
received a wheelchair or scooter in 2000 and 2001.  We found that the quality of wheeled 
mobility devices issued to individuals with MS was inferior to those issued to individuals with 
SCI.   
 
These studies provide preliminary evidence that individuals with MS may be waiting too long to 
transition to the use of wheeled mobility.  When they do receive a wheelchair, veterans with MS 
tend to receive a lower quality of wheelchair.  Finally, we made suggestions for conducting 
longitudinal mobility research in this population, and emphasized the need for future studies.    
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1.  INTRODUCTION 
 
 
 
MS affects approximately 2.5 million people worldwide.  MS is an autoimmune disorder of the 
central nervous system (CNS).  Lesions affect regions of the brain and/or spinal cord.  These 
lesions cause inflammation, demyelination, axonal transection of the region they affect, resulting 
in a wide range of symptoms and physical limitations that vary greatly from one person to the 
next. In addition, the progression of the disease varies from one person to the next. This great 
variability leads to dilemmas in clinical decision making related to mobility. Is there a difference 
in the type of wheeled mobility issued to individuals with MS, when compared to others, such as 
individuals with an SCI, who have a clearer clinical course?  When is the correct time to tell a 
patient to consider a wheelchair or scooter? Will the decision to switch to a mobility device 
cause a decline in strength? These questions do not have clear answers. What is clear is that more 
information would help both the patient and the clinician. 
 
1.1.Quality of Life in Multiple Sclerosis 
“If we intend to measure the effect of treatments on what patients consider important, then we 
would seem to have little choice but to measure health-related quality of life.”(Rothwell PM, 
1998) 
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There is a large body of literature that focuses specifically on various aspects of quality of life in 
people with multiple sclerosis.  Quality of life has been defined as the extent to which hopes and 
ambitions are matched by one’s experience (Calman, 1984).  One study by Nortvedt and 
colleagues demonstrated that people with MS had markedly lower scores on all quality of life 
dimensions when compared to the general population (Nortvedt et al, 1999).  Moreso, Lankhorst 
et al (1996) revealed a substantial deterioration of quality of life measures in individuals with 
MS when compared to other patients with chronic illnesses.  Correlates for a decreased quality of 
life in this population exists in the areas of fatigue, physical disability, neurological impairment, 
depression, and anxiety, to name a few (Merkelbach et al, 2002; Janardhan, & Bakshi 2000; 
Fruehwald et al 2001).   
 
One correlation of particular interest has been seen between quality of life and mobility 
(Aronson, 1997; Evers and Karnilowski, 1996).  It has been reported that 85% of the patients 
with MS reported gait and motor disturbances as their chief complaint (Baum & Rothschild, 
1983).  In fact, studies have shown that this population is particularly predisposed to balance 
deficits and consequent increased risk of falls (Frzovic et al 2000).  Interestingly, motor 
problems and pain were among the primary behaviors causing stress to caregivers of individuals 
with MS (Knight et al, 1997).  Regardless, it is not uncommon for individuals with MS to insist 
on walking despite decreased safety (DeLisa et al, 1985).   
 
Despite compelling studies illustrating an evident need for improved assistive device prescription 
in people with MS, there have been a surprisingly limited number of studies focusing specifically 
on quantitative measures for mobility in MS.  This may help explain the statistic encountered by 
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Perks et al (1997), describing that 59% of individuals in Scotland with MS state their current 
wheelchair does not meet their mobility needs (Perks et al, 1997).  Several factors may 
contribute to this disturbing statistic.  First, Rothwell and colleagues investigated the correlation 
between patients with MS perceptions and assessment of disability with that of their doctors 
(Rothwell et al, 1997).  In this study, investigators found that doctors are not good at estimating 
quality of life in their patients with MS.  While doctors emphasized the physical manifestations 
of the disease, their patients were, instead, much more concerned with the less tangible aspects of 
quality of life, including mental health and vitality.  According to Phillips and Zhao (1993), a 
lack of consideration of the consumer’s opinion when selecting an assistive technology is a 
major factor related to technology abandonment.  If the rehabilitation professional is not 
considering the user’s personal need, inappropriate devices may be issued.  In light of this, it is 
not surprising that a study published by Wheeler and colleagues found that, when compared to 
other wheelchair users, individuals with MS are particularly skeptical, critical, and questioning 
about explanations given by health care providers regarding mobility selection (Wheeler et al, 
1996).   
 
All of the above studies indicate that there exists a great need to explore the types of wheeled 
mobility commonly issued to individuals with MS as well as specific correlations between 
quality of life and assistive technology selection.  It is well known that having an appropriate 
mobility device will significantly influence how a person with a disability perceives his or her 
life, and that, in general, they prefer using mobility equipment to human assistance (Buning et al, 
2000).  For individuals with MS, however, it has been shown that one out of two cases will 
require the assistance of another person for everyday mobility (Baum & Rothschild, 1983).  It is 
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likely that individuals with MS are not receiving mobility devices that allow them to function 
effectively in their environment.   
 
Definitions of disability have increasingly been measured based on the functional limitations 
resulting from the disease, rather than the disease symptoms themselves (Iezzoni, 2000).  
Therefore, emphasis on intervention should be placed on optimizing the ability a person has to 
perform desired tasks, and on overall outcome.  Ironically, however, secondary providers 
continue to predominantly base reimbursement guidelines on quantifiable aspects of disability.  
This poses a serious issue, since, for individuals with MS, alternative mobility devices are often 
necessary to compensate for symptoms that are difficult to assess and quantify, such as fatigue.  
Sadly enough, fatigue is often perceived as not being a legitimate symptom, and many times is 
even dismissed as neurosis (Rolak, 1993; Burnfield & Burnfield, 1978).  Therefore, it is not 
surprising that, though not formally published, it has been the experience of many clinicians that 
assistive technologies in this population are obtained via non-optimal means, such as through a 
friend or family member.  Given the great importance of proper fitting and positioning in 
wheelchair selection (Boninger et al, 2000), the potential for decreased satisfaction with the 
assistive technology and a significantly decreased functional mobility is great.  
 
1.2.Biomechanics of Mobility in Multiple Sclerosis 
1.2.1. Wheelchair propulsion in MS:  
 The Human Engineering Research Laboratory, a VA Center of Excellence, has been dedicated 
to advancing the quality of life in individuals with disabilities through assistive technologies.  
Recently, significant efforts have been made to characterize manual wheelchair propulsion in 
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individuals with MS and to investigate factors contributing to a decreased satisfaction with 
wheelchair function in this population.  Studies like these are especially important since it has 
been recommended that in the later stages of MS, intervention should be focused on the 
impairment level of MS, and should emphasize functional activities and ameliorating 
environmental access (Freeman et al, 2002). 
 
Investigators at University of Pittsburgh were among the first to take a close look at the 
biomechanics of wheelchair propulsion in people with MS (Fay et al, 2004).   In this study, the 
biomechanics of wheelchair propulsion in people with MS was compared to other expert 
wheelchair users.  Their study showed that individuals with MS propel their wheelchair 
significantly slower than control counterparts, and are actually unable to attain a target speed of 
1.2 m/sec, considered a standard for functional mobility (Lerner-Frankiel et al, 1986).  Further, 
kinematic analysis showed that these individuals propel their wheelchair in the least efficient 
propulsion style, expending more energy than control counterparts (Fay et al, 2004).  Boninger et 
al (2002) has shown that there are four different patterns for propelling a manual wheelchair.  
These four patterns include 1) semicircular pattern (SC), 2) single looping over propulsion 
(SLOP), 3) double looping over propulsion (DLOP), and 4) the ARC pattern.  Of these four 
styles, the SC pattern was shown to be the most efficient and the least likely to contribute to 
upper extremity injury.  On the other hand, the ARC pattern was shown to be the most energy 
consuming, and the least efficient.  Fay et al (2004) showed that individuals with MS were much 
more likely to use the ARC pattern for manual wheelchair propulsion when compared to other 
manual wheelchair users.  These results are particularly significant in this population where 
energy conservation is so essential.  Further analysis revealed that people with MS actually 
 5
generated a “braking moment” with each stroke of the wheelchair (Fay et al, 2004).  Using 
bilateral SmartWHEELS (Cooper et al, 1997), capable of measuring three-dimensional forces and 
moments, it was shown that with each wheel contact and release, these individuals produced a 
moment opposite to the direction of forward propulsion (Fay et al, 2004).  Considering these 
significant findings, we decided to investigate further the ability of current clinical measures to 
predict the ability to functionally propel a manual wheelchair in this population.  The clinical 
measures tested, including manual muscle testing, sensory testing, and spasticity rating were not 
sensitive enough to predict this functional limitation.  Therefore, it may be difficult for clinicians 
to recognize the need for mobility device intervention at an early enough stage of disease 
progression, before participation in daily activities and quality of life are affected.   
 
1.2.2. Strength testing and MS:   
In a study comparing 15 individuals with MS to 15 control subjects, Lambert et al (2001) found 
that individuals with MS had peak torque production 25.7% and 20.8% lower than controls for 
dominant flexors and for non-dominant flexors of the lower extremity, respectively.  While the 
mechanism for muscle weakness in MS is still unclear, some findings have provided important 
information in this area.  First, Kent-Braun and colleagues found a 26% reduced muscle fiber 
cross-sectional area relative to controls, a comparable percentage to the torque production 
findings of Lambert and colleagues (Kent-Braun et al, 1997).  Even so, Lambert et al (2001) 
demonstrate that fat free mass differences did not account for the differences in strength between 
individuals with MS and control subjects.  In their study, there was no significant difference in 
force production.  Instead, they concluded that strength differences were attributed to a decreased 
muscle quality.  Along these lines, Rice et al (1992) conducted a study looking at the motor 
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neuron firing rates during an isometric exercise protocol and found rates to be significantly lower 
than seen in control subjects.  This indicates a decreased ability for muscle activation in this 
group of individuals.  Haan and colleagues (2000) had similar findings when they investigated 
the contractile and fatigue properties of the quadriceps muscle in 17 people with MS.  They 
found that individuals with MS were only able to generate about ¾ of the maximal force-
generating capacity of their muscles.  The force and speed characteristics, however, were not 
significantly different from control subjects, again supporting the idea that strength changes are 
not a result of an impaired contractile mechanism.  Finally, studies by Kent-Braun et al have 
demonstrated a higher prevalence of fast-twitch muscle fibers in the group with MS when 
compared to control counterparts (Kent-Braun et al, 1996).  Fast-twitch muscle fibers have a 
greater reliance on anaerobic energy supply and demonstrate a reduced muscle oxidative 
capacity.  Therefore, an increased percentage of this muscle fiber type would contribute to a 
decreased endurance and an increased fatigability.   
 
Fay et al (2001) highlighted the need for more sensitive clinical measures of strength in 
individuals with MS.  Their study compared the isokinetic strength of individuals with MS as 
determined with the use of a BioDex System 3 (Biodex Medical, Shirley, NY) against a manual 
muscle test grade (American Spinal Injury Association and International Medical Society of 
Paraplegia, 1996) as determined by a physical or occupational therapist.  They found that the 
MMT results were not correlated with isokinetic measures of strength, indicating that the MMT 
may not be the most appropriate test for quantifying strength in populations with MS.  Additional 
research, therefore, is needed for the development of new, more effective clinical examination 
that more accurately describes the strength of individuals in this population (Fay et al, 2001).   
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 1.2.3. Fatigue testing and MS:   
Murray et al (1985) found that up to 40% of individuals with MS claim that fatigue is the most 
serious symptom they experience.  With this in mind, several studies have concentrated efforts 
on investigating the mechanism of fatigue in MS.  Certain aspects of fatigue have been well 
established in this population.  First, it is generally accepted to be strongly temperature 
dependent (Krupp et al, 1988).  Also, people with MS commonly describe their fatigue as a 
general lack of physical energy rather than a weakness of a specific muscle group (Krupp et al, 
1988).  This often leads to a cycle of fatigue→ decreased activity→ increased fatigue.  One 
study by Sheean et al (1997) took an electrophysiological (EMG) look at the mechanism of 
fatigue in MS.  All subjects performed a fatiguing protocol while EMG data were collected.  
Results revealed evidence of an exercise-induced reduction in force generation. Interestingly, 
this reduction in strength was only evident with sustained contraction.  This is supported by 
findings from Schwid et al (1999) that demonstrated that static fatigue was not associated with 
strength of the same muscle.  Therefore, it may be difficult, clinically, to detect fatigue in this 
population, since most standardized clinical evaluation tools do not incorporate prolonged 
measures of strength and ability.  Sheean et al (1997) also found no correlation between the 
amount of inducible fatigue and the amount of self-reported fatigue experienced in everyday life, 
contributing further to the mystery of fatigue in this population.  This is further supported by 
findings of Sharma and colleagues (1995), where they reported that muscular fatigue did 
correlated with clinical evidence of upper motor neuron dysfunction, and with metabolic changes 
during exercise, but not with perceived fatigue ratings. 
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Controversy has traditionally existed regarding how much physical exercise is necessary and 
beneficial versus how much will actually contribute to an increased exacerbation rate.  
Commonly individuals with MS experience a decline in strength and an increased fatigue 
concurrent with an increased core body temperature (Poinchtera-Mulcare, 1993).  None-the less, 
it has become more and more widely accepted that people with MS should be encouraged to 
participate in regular physical activity for improved cardiovascular conditioning as well as for 
the psychosocial benefits that often accompany physical activity (Petajan et al, 1996) and that 
individuals with MS can, in fact, exercise with no detrimental effects (Poinchtera-Mulcare, 
1993).  Even so, care must be taken to control external variables such as the level of exertion, 
environmental temperature, etc.  This is important to keep in mind when considering delaying 
mobility device prescription for the sake of increasing physical activity.  If this were the case, an 
especially hot day, or a day of increased fatigue symptoms would inevitably lead to a decreased 
ability to perform everyday tasks, the very definition of disability. 
 
1.2.4. Gait in MS:  
 The plaque-like lesions that characterize MS may affect one or many control centers of the 
CNS, including the vestibular, visual, and/or somatosensory centers.  This being the case, 
balance, and consequent falls may be a serious problem.  In a study by Cattaneo et al (2002), 50 
patients with MS were recruited to quantify the risk of falls and to report on specific variables 
associated with falls in this population.  Through outcome questionnaires as well as objective 
measures of strength, spasticity, and transfer skills, a regression analysis was performed.  
Subjects were divided into a faller group or a non-faller group, based on the total number of falls 
in the two months prior to data collection.  Of all the subjects collected, 32% reported 2 or more 
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falls in the two months prior to the study, and 59% reported at least one fall two months before. 
For people who were classified as fallers, performance on balance testing was significantly 
worse when compared to non-fallers.  Other characteristics of the faller group included the 
inability to run, walk, walk on an uneven surface, or pick up an item off the floor.   
 
1.3.Purpose 
The significant limitations often experienced by individuals with MS in the areas of ambulation 
and manual wheelchair propulsion have been highlighted above.  The lack of research in this 
area as it relates to assistive technology intervention is evident, leading to what we believe to be 
a high incidence of improper assistive technology prescription.  All of this will have a profound 
effect on overall quality of life in this population.  Despite this, it is undeniable that the transition 
to alternative forms of mobility is often perceived as an indicator of decline in overall function 
and of increasing disability.  People perceive an increased reliance on assistive technology as a 
hindrance to maintaining strength and conditioning.  However, this must be taken very carefully 
in this population, considering fatigue is what frequently emerges as the one symptom that most 
commonly interferes with physical functioning (Krupp et al, 1988).  Energy conservation 
strategies are commonly recommended for the management of fatigue.  In this, the patient is 
advised to preserve their energy as much as possible for necessary and desired tasks.  
Undoubtedly, therefore, a tremendous discrepancy often exists between what the individual, the 
health care practitioner, and/or the secondary providers believe is optimal intervention, versus 
what will actually lead to a maximized everyday functioning and, ultimately, quality of life.   
The purpose of this project was three-fold:  1. to examine signs that a switch to wheeled mobility 
might be indicated for individuals with MS and to characterize individuals with MS who are 
 10
about to switch to wheeled mobility, 2. to investigate physiological and quality of life changes 
accompanying a change in primary means of mobility in persons with MS and 3.  to determine 
whether there is a difference in the type of wheeled mobility issued to veterans with MS when 
compared to veterans with an SCI.  These aims were addressed in a series of three studies.  The 
first study investigates the characteristics of individuals with MS who are about to transition to 
wheeled mobility, as well as the usability of functional ambulation and self-reported fatigue as a 
surrogate measure of declines in physical activity and participation.  The second study 
investigates the physiological and quality of life changes that accompany a change in primary 
means of mobility, and gives methodological considerations for conducting longitudinal mobility 
research in individuals with MS.  Finally, the third study investigates whether a difference exists 
in the type of wheeled mobility issued to veterans with MS when compared to veterans with a 
spinal cord injury (SCI).  Through these studies, we hope to provide individuals with MS and 
their clinicians with the information necessary to make more informed decisions regarding 
mobility device selection, ultimately leading to and increased quality of life.   
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2.1.ABSTRACT  
 
Background:  The purpose of this study was to characterize individuals with MS who are about 
to transition in their primary means of mobility.  Additionally, we investigated the correlation 
between functional ambulation measures and subjective fatigue with physical activity, quality of 
life and participation.  Methods:  Seven individuals with clinically definite MS who had a 
prescription for a new wheeled mobility device participated in this study.  All subjects completed 
the Timed 25 Foot Walk Test (T25FW), and completed three questionnaires: the Modified 
Fatigue Impact Scale (MFIS), the Short Form-36 (SF-36), and the Craig Handicap Assessment 
Reporting Technique (CHART).  Study participants also monitored their daily activity using a 
pedometer for one week.  A Spearman’s correlation coefficient was used to relate the T25FW 
and physical activity, as well as with variables of the SF-36 and the CHART.  In addition, a 
Spearman’s correlation was used to measure the relationship between MFIS and variables of the 
SF-35 and the CHART.  Results:  The T25FW was significantly correlated with average daily 
steps (p=0.023), and the MFIS was significantly correlated with both the mobility and 
occupational scores of the CHART (p= 0.012 and 0.05, respectively).  Discussion:  The T25FW 
and the MFIS may be good indicators of daily physical activity and participation in daily 
activities, respectively.  Future investigations should seek to define scores for both of these 
measures that clinicians could use to determine when is the most appropriate time to transition to 
wheeled mobility for people with MS.    
 
Key Words (7-10): Multiple Sclerosis, Walking, Gait, ambulation, Fatigue, T25FW, physical 
activity, mobility, pedometer 
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2.2. INTRODUCTION 
 
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, affecting 
approximately 2.5 million people worldwide, and 400,000 people in the United States 
(www.nmss.org). Primary symptoms reported in individuals with MS include muscle weakness, 
spasticity, and fatigue, among others.  These symptoms can affect how effectively individuals are 
able to participate in activities of daily living.  Muscle weakness and fatigue can lead to 
decreased physical activity levels, deconditioning, increased risk for falls, impaired mobility, and 
ultimately, decreased quality of life.  This can become a vicious cycle leading to increased 
disability and dependence.  Baum and Rothschild reported that over 50% of individuals with MS 
require assistance for daily mobility (1983).   
It is very difficult to know if and when to transition from ambulation to wheeled mobility as a 
primary means of mobility.  Many individuals believe transitioning to a wheelchair too soon will 
lead to increased deconditioning and subsequent increased disability (Iazonni et al, 2003).  They 
believe prolonging ambulation as long as possible will allow them to maintain their lower 
extremity strength.  On the other hand, it is possible that the increased effort associated with 
delaying the transition to a wheelchair as a primary means of mobility may lead to increased 
subjective feelings of weariness, weakness, and/or lack of energy (Merkelback et al, 2002).  
Fatigue has been reported to be the number one symptom in persons with MS affecting daily 
activity (Krupp et al, 1988).  Increased subjective fatigue will ultimately lead to a decreased 
ability to participate in activities of daily living.  It may be for this reason that individuals with 
MS have lower self-perceived quality of life scores when compared to individuals with other 
chronic disorders (Lankhorst et al, 1996).  This is significant since quality of life has been 
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defined as the extent to which hopes and ambitions are matched by one’s experience (Calman, 
1984).  It is important that clinicians have quick and effective tools for measuring how active 
individuals with MS are in their daily lives, and how much fatigue is interfering with their ability 
to participate in activities of daily living.  Decreased physical activity and participation may be 
an indication that a mobility device intervention is needed.   
The primary objectives of this paper are to 1.  describe individuals with MS who are about to 
transition in their primary means of mobility, 2.  determine how well the Timed 25 Foot Walk 
test (T25FW) estimates the average number of daily steps in ambulatory persons with MS who 
are planning to transition in their primary means of mobility, and 3.  determine how self-reported 
fatigue correlates with both quality of life and participation in activities of daily living in this 
population.    
 
 
 
2.3.METHODS 
 
2.3.1. Participants 
This study included ambulatory individuals who had clinically definite MS as determined using 
the McDonald criteria (McDonald et al, 2001), and who were referred to an assistive technology 
clinic for a new wheelchair (manual wheelchair, power wheelchair, or scooter).  At the time of 
enrollment, subjects who were currently ambulating as their primary means of mobility 
(Expanded Disability Status Scale score of ≤ 7.0) had a prescription for a new wheelchair or 
scooter, but had not yet received their new mobility device.  All individuals were between the 
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ages of 18 and 65 years, had no significant cognitive impairment (Mini Mental Scale Exam score 
of > 26 (Folstein et al, 1975)), and were not clinically depressed (CES-D score of <22 (Radloff, 
1977)).  Any subject who had an MS exacerbation within 3 months of recruitment was excluded 
from the study.  Subjects were recruited through the Center for Assistive Technology at the 
University of Pittsburgh.  The Highland Drive Veterans Administration Investigational Review 
Board approved the study, and all study participants provided informed consent prior to testing. 
 
2.3.2. Procedures 
2.3.2.1. Questionnaires: 
Quality of life was measured using the SF-36 Health Survey (Freeman et al, 2000), widely 
acknowledged as the “Gold Standard” for generic measures of health status.  The internal 
consistency, reliability, and validity of this survey as a measure of health-related quality of life in 
multiple sclerosis have been confirmed (Freeman et al, 2000; Ware et al, 1993).  There are ten 
outcome variables from the SF-36 including: 1. physical functioning (PF)  2. social functioning 
(SF),  3. role limitations physical (RP),  4. bodily pain (BP),  5. general medical health (GH),  6. 
mental health (MH),  7.  role limitations emotional (RE),  8.  vitality (VT),  9. composite physical 
health status (PCS) and  10. composite mental health scores.  Limitations, such as marked floor 
and ceiling effects, as well as poor responsiveness for change have been demonstrated in 
individuals with MS (Freeman et al, 2000).  Therefore, it has been recommended that this tool be 
used in conjunction with other measures.   
 
All subjects also completed the Craig Handicap Assessment and Reporting Technique (CHART), 
a 27-question outcome tool used for measuring quality of life in terms of participation in 
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everyday activities as well as in social activities (Whiteneck et al, 1992).  Three outcome 
variables of the CHART were considered: the physical independence score, the mobility score 
and the occupation score.  Two additional questions, not included in the calculations for scoring 
CHART domains were added which asked the subjects whether or not they had fallen in the last 
month, and if so, how many times.   
 
Self reported fatigue over the four weeks prior to the test visit was assessed using the Modified 
Fatigue Impact Scale (MFIS)(Fisk 1994a, Fisk 1994b).  The MFIS is a shortened version of the 
40-item Fatigue Impact Scale (FIS) questionnaire designed to assess the problems in patients’ 
quality of life that they attribute to their symptoms of fatigue.  In the initial validation studies, 
FIS subscales had good internal consistency (Fisk et al, 1994b).  The fatigue guidelines 
development panel of the MS Council for Clinical Practice Guidelines (1998) has recommended 
the MFIS as the main outcome measure for assessing MS-related fatigue.   
 
2.3.2.2. Objective Measures: 
All participants underwent neurological testing to obtain an Expanded Disability Status Scale 
(EDSS) score (Kurtzke, 1983).  Ambulatory function was assessed using the timed 25-foot walk 
test (T25FW) where subjects were instructed to walk 25 feet as fast as they were safely able, 
using whatever type of walking aid they felt was necessary.  In order to maintain consistency 
between subjects, instructions for completing the T25FW were scripted, and all testing took 
place on the same 25-foot tiled surface.   
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At the end of laboratory testing, subjects were given a pedometer, and instructed to wear the 
pedometer from the time they woke up to the time they went to bed for 7 days.  Each night 
before going to bed, subjects were asked to record the pedometer reading on a form provided by 
our laboratory.  Subjects were called periodically throughout the 7 days to ensure that they were 
wearing the pedometer and recording the readings.  If the subject forgot to wear the pedometer 
one day, they were asked to continue wearing the pedometer for an extra day in order to make 
sure that every subject had 7 full days of recorded pedometer readings.  Subjects wore a Yamax 
Digi-Walker ™ pedometer at their hip, attached with a clip to the waistband of their pants.  The 
Digi-Walker was chosen because it has been shown to be among the most accurate for counting 
steps (Schneider et al, 2004)   
 
2.3.3. Statistical Analysis 
Subject characteristics, including age and time since diagnosis, as the MFIS, SF-36 domain 
scores, the CHART outcome variables, and T25FW scores are reported as means plus or minus 
standard deviations.  EDSS scores are reported as frequency counts.   
For the week-long ambulation monitoring, average daily recorded steps are presented as well as 
the total steps recorded over the course of one week
 
Because the sample size was small, nonparametric statistics were completed to calculate 
correlations.  A Spearman’s two-tailed correlation was to determine the relationship between: 
• T25FW and average daily steps ambulated 
• the ten individual measures from the SF-36 and the T25FW 
• three outcome variables of the CHART and the T25FW 
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• MFIS score with the ten individual measures from the SF-36 
• MFIS score with the 3 outcome variables of the CHART 
• MFIS score with T25FW  
Data were considered statistically correlated at p≤0.05.  This cut-off point was chosen since our 
sample size was small, and since this was a pilot study to identify whether the T25FW and the 
MFIS could be used as surrogate tools for estimating quality of life and daily participation.  
Therefore, if our preliminary findings reveal a correlation between variables, this will indicate a 
need for further investigation.   
 
 
 
2.4.RESULTS 
 
2.4.1. Participants 
Seven females with MS participated in this study.  The average age of the participants was 51.2 
+/- 6.8 years (range of 48.0 to 63.4) and the average time since diagnosis with MS was 10.4 +/- 
6.8 years (range: one year to 19 years).  Five of the subjects had fallen at least once in the last 
month.   
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2.4.2. Procedures 
2.4.2.1. Questionnaires:  
The MFIS is a 5-item questionnaire and possible scores range from 0 to 20, with ‘20’ being the 
maximal effect of fatigue on ability to perform everyday activities.  Participants in this study had 
an average score on the MFIS of 14+/-3 (range of 9 to 19).   
 
A comparison between SF-36 domains in the US general population versus subjects with MS is 
shown in Table 1.  In our study, individuals with MS scored considerably lower on all domains 
of the SF-36, with the exception of RE and MH, where they scored higher than published norms. 
 Table 1SF-36 average domain scores (Physical Functioning (PF), Role Physical (RP), Bodily 
Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), 
Mental Health (MH), Physical Composite Score (PCS), and Mental Composite Score (MCS)) in 
the general US population vs. subjects with MS 
Population PF RP BP GH VT SF RE MH PCS MCS 
General US 84 81 75 72 61 83 81 75 50 50 
MS 35 25 52.3 48.4 20 53.6 85.7 85.7 26.8 53.5 
*General US population scores taken from http://www.pdsa.org/conference2004/265,8, 
 
The maximum score for each domain of the CHART is 100, considered to be the level of 
performance of a typical, non-disabled individual.  In this study, individuals with MS had an 
average physical independence score very close to non-disabled individuals (97.5), however, 
scored approximately 25% lower than non-disabled individuals in the mobility score and the 
occupation score (75.6 and 75.7, respectively). 
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2.4.2.2. Objective Measures: 
When considering functional mobility, our sample group was homogenous, according to the 
EDSS.  Five of the subjects in this study had an EDSS score of 6.0 and used a single point cane 
for ambulation.  The remaining two subjects had an EDSS score of 6.5 and used a wheeled 
walker for ambulation (subjects # 3 and #6).  The EDSS ranges from 0 to 10, with 0 being no 
impairment, and 10 being death as a result of MS (Kurtzke, 1983).  An EDSS score of 6.0 is 
given when the individual requires intermittent or constant unilateral assistance (cane, crutch or 
brace) to walk 100 meters with or without resting.  An EDSS score of 6.5 is given when the 
individual requires constant bilateral support (cane, crutch or braces) to walk 20 meters without 
resting.   
 
The average time to complete the T25FW was 13.1 +/- 5.0 seconds (0.61 m/sec), with a range of 
6.4 to 21.8 seconds.  The average daily number of steps was 2,047 +/ 538.1 (Table 2). The 
T25FW and the average number of steps ambulated per day was significantly correlated at p= 
0.023 (r2 = 0.5388)(Figure 1).   
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Figure 1 Spearman’s correlation between T25FW and average daily number of steps 
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The T25FW was not significantly correlated to any of the outcome variables of the SF-36, the 
CHART, or with the MFIS.   
Table 2 Pedometer readings for all subjects 
Subject # Average daily 
number of steps 
Total number 
steps over 7 days  
Number of times 
fallen in last 
month 
1 
 
1,718 12,025 10 
2 
 
2,744 19,211 0 
3 
 
2,217 15,519 >20 
4 
 
1,646 11,524 1 
5 
 
2,306 16,142 1 
6 
 
2,484 17,387 0 
7 
 
1,213 7,958 2 
Average of 
Allsubjects 
2,047 14,249 
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While the MFIS score did not correlate with any of the SF-36 outcome variables, it significantly 
negatively correlated with the CHART mobility score (p=0.012), and the CHART occupation 
score (p= 0.05). Therefore, as subjects reported increased self-reported fatigue, they 
demonstrated a decreased mobility and occupation scores of the CHART.   
 
 
2.5.DISCUSSION 
 
It is undeniable that the transition to alternative forms of mobility is often perceived as an 
indicator of decline in overall function and of increasing disability.  People perceive an increased 
reliance on assistive technology as a hindrance to maintaining strength and conditioning.  
However, for the MS population, fatigue frequently emerges as the one symptom that most 
commonly interferes with physical functioning (Krupp et al, 1988).  Therefore, energy 
conservation strategies are commonly recommended for the management of fatigue.  The patient 
is advised to preserve their energy as much as possible for necessary and desired tasks.  
Undoubtedly, a discrepancy often exists between what the individual, the health care 
practitioner, and/or the secondary providers believe is optimal intervention, versus what will 
actually lead to a maximized everyday functioning and, ultimately, quality of life.  We conducted 
this study in order to describe a population of individuals with MS who are about to transition to 
a new means of primary mobility and to correlate clinical tests of gait speed and subjective 
fatigue with measures of quality of life and daily participation.   
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2.5.1. Participants 
All the subjects who participated in our study were female.  While MS does primarily affect 
females, 38 percent of individuals with MS are males 
(http://health.yahoo.com/health/ceters/women/_19238199.html).  The average age of individuals 
who are transitioning to the use of a wheeled mobility device in our study was 51.2 +/- 6.8.  This 
is in line with a study published by Baum and Rothschild (1983) which showed that the average 
age of individuals with MS needing mobility assistance both indoors and outdoors is 52 years.  
However, in this same study, the average duration of disease of those individuals needing 
mobility assistance both indoors and outdoors was 28.9 years, whereas it was only 10.4 +/- 6.8 in 
our sample population.   
 
 
2.5.2. Procedures 
2.5.2.1. Questionnaires: 
When comparing SF-36 domain scores to the general population, individuals with MS from this 
study scored lower on all domains measuring the effect of physical functioning on quality of life.  
For the two domains quantifying mental and emotional health (RE and MH), individuals with 
MS scored higher than the average given for the general US population.  This result indicates 
that the decreased quality of life seen in individuals with MS who are transitioning in their 
primary means of mobility is primarily due to physical, and not emotional or cognitive, 
impairments.  This is not surprising since only individuals without significant depression and no 
cognitive impairments were included in this study.   
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Individuals with MS scored an average of 97.5% out of a possible 100% on the physical 
independence domain of the CHART.  This domain incorporates the ability of the individual to 
maintain an independent existence 
(http://www.craighospital.org/Research/Disability/CHART%20Manual.pdf).  This is consistent 
with results found from the SF-36, since the physical independence domain of the CHART 
included the ability of the individual to instruct and direct others who are assisting them.  
Therefore, this measure is not purely a function of physical ability, as the name might suggest, 
but includes cognitive abilities.  On the other hand, individuals with MS scored lower than non-
disabled individuals for both the mobility and occupation scores of the CHART, which are both 
primarily measures of physical ability.  According to the Craig Hospital guide for using the 
CHART (http://www.craighospital.org/Research/Disability/CHART%20Manual.pdf), the 
occupation score measures the individual’s “ability to occupy time in the manner customary to 
that person’s sex, age, and culture.” This score is calculated by asking the subject to report the 
time spent in various activities, while weighting the relative value society places on different 
activities.  For example, priority is given to employment, schooling and active homemaking and 
maintenance.  According to the same reference, the mobility score measures the ability of the 
individual to get around in their environment.  This is estimated by asking the subject to report 
the hours per day out of bed, days per week out of the house, nights per year spent away from 
home, accessibility of the home, and transportation utilization.   
 
The MFIS was significantly correlated to the mobility score and the occupation score of the 
CHART.  Therefore, variables of the CHART primarily measuring functional ability are related 
to the individual’s self-reported fatigue, whereas the same is not true when considering the 
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relationship between self-reported fatigue and cognitive functioning, as measured by the physical 
independence score of the CHART.  From these results, we believe that the 5-item MFIS may be 
a quick and effective clinical tool surrogate for estimating the amount of time spent in important 
daily activities, and how effectively the individual moves about in their own surroundings.   
 
2.5.2.2. Objective Measures: 
The average number of steps taken/day for all our subjects was 2,047.  This is much lower than 
the average number of steps taken in unimpaired individuals, which different research studies 
have described to be between 7,000 and 13,000 (Miller and Brown, 2004, Schneider et al, 2004, 
Tudor-Locke et al, 2004, Tudor-Locke et al, 2001).  Even when excluding volitional physical 
activity such as participation in sport or exercise, evidence supports that 6,000-7,000 steps/ day 
is representative of normal daily activity (Tudor-Locke et al, 2002).  It is now widely accepted 
that 10,000 steps/day be considered a level of physical activity found in “healthy adults”, and 
there is growing evidence that this level of physical activity is associated with indicators of good 
health such as decreased body fat and lower blood pressure (Tudor-Locke et al, 2001).  
Individuals with an average of less than 5,000 steps/day have been shown to be more likely to be 
classified as obese, and may be considered a satisfactory index for a sedentary lifestyle (Tudor-
Locke et al, 2004). 
 
It has been shown that pedometers underestimate walking distance in individuals with slower 
gait (Melanson et al, 2004), as is the case for the individuals included in this study.  However, 
because our subjects ambulated fewer than half of the number of daily steps than what is 
considered sedentary, we expect that, even accounting for the fact that the pedometer 
 33
underestimates steps in individuals with a slower gait velocity, these individuals are not 
maintaining a healthy level of physical activity.  These results have shown that individuals with 
MS are considered to be sedentary at the time when the decision is made to transition to a 
wheelchair, and that these individuals are not engaging in a sufficient amount of physical activity 
to be considered “healthy”.  Therefore, since these individuals are already sedentary, it might be 
late for a transition.  It is possible that they should transition sooner, before their decreased 
ability to ambulate begins to affect their activity level.  Furthermore, by relying on ambulation 
for regular mobility, they are likely to have increased energy expenditure, ultimately increasing 
their subjective fatigue.  An increased subjective fatigue will undoubtedly decrease their ability 
to participate in important daily activities, as we have seen when correlating fatigue with the 
CHART mobility and occupation scores.     
 
When considering the T25FW, individuals with MS ambulated at 0.63m/sec.  This is much 
slower than previously reported functional walking speed of 1.2m/sec, the speed required to 
safely cross a street within the time allowed by a traffic signal (Lerner-Frankiel et al, 1986).  We 
also found the T25FW, an easy to administer tool that may have good potential at estimating the 
amount of daily physical activity in persons with MS.  Ideally, clinicians would use this tool to 
be aware of physical activity in persons with MS.  When the individual is not participating in a 
sufficient amount of physical activity to maintain a healthy lifestyle, and yet is spending a 
significant amount of energy ambulating as evidenced by increased fatigue, the clinician may 
recommend that the individual transition to a new form of primary mobility.  It is our belief that 
implementing this type of system will lead to an earlier transition to a wheeled mobility, which 
would result in a decreased subjective fatigue, and ultimate increased quality of life.   
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2.5.3. Limitations 
As previously mentioned, a limitation of this study is the small sample size.  Future studies 
should include more individuals with MS, both male and female, who are transitioning in their 
primary means of mobility.  In addition, with a larger sample size, it would be beneficial to 
investigate the relationship between outcome variables in individuals with a wider range of 
ambulatory ability.  For example, is the T25FW more effective at predicting physical activity in 
persons with no ambulatory restrictions when compared to individuals who require the use of a 
walking aid?  This is likely to be the case, since it has been suggested that pedometers may 
underestimate walking activity in individuals who ambulate at slower speeds (Melanson et al, 
2004).  The average daily steps of the individuals in our sample ranged from 1,283 to 2,744.  
While it is likely that the pedometer is underestimating the actual number of steps taken, we 
believe it is unlikely that it is underestimating activity to the extent that they would not longer be 
considered sedentary.  Future studies should also investigate the reliability of pedometers in 
individuals with altered gait patterns, as is commonly seen in persons with MS.  One study 
investigated the ability of pedometers to estimate physical activity in individuals with 
hemiparetic stroke (Macko et al, 2002).  This study found that the conventional pedometer does 
not accurately measure number of steps and cadence in this population.  However, because the 
gait impairment in this population is unilateral, these findings are not necessarily true to 
individuals with MS, who collectively demonstrate a wide variety of gait patterns.  
 
We were able to find a correlation between the MFIS and participation in daily activities, as well 
as a correlation between the T25FW and average daily physical activity; however, we did not 
establish definitive clinical indicators of the need for mobility device intervention.  Ideally, 
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clinicians would have ranges of time to ambulate 25 feet or of self-reported fatigue that would 
alert them that a transition to wheeled mobility might be indicated.  Future studies should seek to 
determine specific scores at which clinicians should begin to consider mobility device 
intervention.   
 
 
2.6.CONCLUSION 
 
Individuals from our study who were about to transition in their primary means of mobility did 
not ambulate at a functional speed, even when asked to ambulate as fast as they were able for the 
T25FW.  They were also found to be sedentary, with lower physical measures of quality of life 
when compared to the general population.   
 
The T25FW was found to correlate significantly with the average daily number of steps in this 
population.  Similarly, the MFIS correlated significantly with physical functioning aspects of the 
CHART.  Taken together, the T25FW and the MFIS may be quick and easy-to-administer tools 
for estimating physical activity and participation in daily activities.  This information could be 
useful to clinicians about when to consider wheeled mobility intervention.   
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3.1. ABSTRACT 
 
Background:  To date, no empirical evidence exists that investigates what physical and quality 
of life changes individuals can expect as they transition in primary means of mobility.  The 
purpose of this project was to examine changes in quality of life measures, muscle strength and 
muscle fatigue that parallel changes in functional mobility.  Methods:  Individuals with chronic 
conditions who had a prescription for a new type of wheeled mobility participated in this study.  
Testing took place over three visits: upon wheeled mobility prescription (V1), upon wheeled 
mobility receipt (V2), and after using the wheeled mobility for a time equivalent to the time 
between V1 and V2 (V3).  Functional mobility was assessed using the Timed 8-meter Walk test 
(T8) and a timed 8-meter wheelchair propulsion trial.  Isometric muscle strength and fatigue was 
tested using the Biodex 3.  Quality of life, participation in daily activities, and self-reported 
fatigue was assessed using the Short Form-36 (SF-36), the Craig Handicap Assessment 
Reporting Technique, and the Modified Fatigue Impact Scale, respectively.  Results:  Eleven, 
six and 3 individuals completed V1, V2, and V3 testing, respectively.  At V1 testing, the average 
speed to complete the T8 was 0.63m/sec.  This was the same average speed for the manual 
wheelchair propulsion trial at V1.  All individuals who completed the T8 over the three trials had 
less than 20% change between visits.   Only 6 subjects could complete Biodex testing at V1 
secondary to not meeting testing criteria, and only 1 subject completed testing over all three 
visits.  For this individual, muscle strength of the lower extremity muscles tested actually 
increased after wheeled mobility intervention.  Increases in SF-36 scores seemed to be related to 
amount of wheeled mobility use over time.  Discussion:  A transition to the use of wheeled 
mobility may not lead to the expected decrease in muscle strength and ambulatory ability.  
Furthermore, the benefit of mobility device use on quality of life measures seems to parallel 
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amount of device use.  Future studies should further investigate the benefits to be gained from a 
transition to a wheeled mobility for people with chronic conditions.      
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3.2.INTRODUCTION 
 
Multiple sclerosis (MS) presents with an unpredictable pattern of symptoms.  This means that 
individuals with MS have limited knowledge about their personal prognosis.  This may lead to a 
state of uncertainty, and has the potential to make decisions regarding treatment options difficult.  
One such decision often includes when and how to transition to an increased reliance on wheeled 
mobility.  
 
There have been several articles published which recognize mobility impairment as a major 
functional limitation for individuals with MS (Baum and Rothschild, 1983; Perks et al, 1997; 
Finlayson et al, 2003; Fay et al, 2004).  Yet, despite the prevalence of mobility impairment in 
individuals with MS, and its use as a measurement of disease progression, most research studies 
considering mobility status use functional mobility as an outcome measure for treatment 
interventions such as exercise programs or pharmacologic treatments (Dario et al, 2001; Wiles et 
al, 2001; Wiles et al, 2003; DeBolt and McCubbin, 2004; Ozgocmen et al, 2005).  Few studies 
focus on improving the efficacy of mobility device prescription in this population.   
 
The lack of research considering the appropriate time to transition to an alternative form of 
primary mobility is likely to lead to suboptimal daily functioning in persons with MS.  It has 
been reported that 85% of the patients with MS reported gait and motor disturbances as their 
chief complaint (Baum & Rothschild, 1983), and studies have shown that individuals with MS 
are particularly predisposed to balance deficits and consequent increased risk of falls (Frzovic et 
al 2000).  In a study investigating the prevalence of falls in individuals with MS, of all the 
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subjects collected, 32% reported 2 or more falls in the two months prior to the study, and 59% 
reported at least one fall during this same time (Cattaneo et al, 2002).   
 
Often, patients are prescribed manual wheelchairs for mobility assistance in order to improve 
mobility while decreasing fatigue and the risk of falls.  It has been reported that, among those 
individuals with MS who use a manual wheelchair, a majority state that their wheelchair does not 
meet their mobility needs (Perks et al, 1993).  Recent research indicates that people with MS are 
ineffective at propelling a manual wheelchair, and are unable to do so in a manner that is 
consistent with the demands of everyday tasks (Fay et al, 2004).  The next logical step, therefore, 
would be a progression to a powered means of mobility.  Yet, to the patient and to the secondary 
payers, this may seem like a drastic overall change.  A power wheelchair has traditionally been a 
symbol of increased disability and dependence, and resistance to such a modification is often 
great.  Among practitioners, it is also commonly believed that a transition to manual and 
motorized wheelchairs will accelerate declines in strength and functional abilities through disuse.  
As a result, a dichotomy exists between what might be most empowering for the individual, 
versus the acceptance of the assistive technology by patients and prescribers.   
 
In a study by Boeije and Janssens (2004), individuals with MS were surveyed about their 
perceived seriousness of wheelchair usage.  From the responses, subjects were divided into three 
groups.  The largest group was characterized by individuals for whom the loss of mobility 
represented “loss of independence, a shrinking social world, adaptations to the house or even 
having to move, and the need for help.”  Ultimately, however, these individuals felt they would 
get used to using a wheelchair.  The second group said that usage of a wheelchair for mobility 
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would be the worst thing to happen to them.  These individuals feared losing all their 
independence and being treated differently by others.  The smallest of the three groups were 
those individuals who saw the use of a wheelchair as a minor inconvenience.  Along these lines, 
another study by Janssens et al (2003) showed that differing levels in disease impairment alter 
the individual’s perception of using a wheelchair. That is, in individuals with MS, those with 
greater functional disability view the use of a wheelchair as “less serious” when compared to 
those individuals who are less functionally affected.  It can be argued, that as one’s mobility 
becomes more limited, they increasingly view a wheelchair as an enabler, rather than a symbol 
of disability.  These studies reveal that many individuals with MS possess misconceptions about 
the impact of transitioning to a wheelchair as their primary means of mobility.  For this reason, 
these individuals may feel the need to delay a transition as long as possible. 
 
The significant limitations often experienced by individuals with MS in the areas of ambulation 
and manual wheelchair propulsion are undeniable, and the lack of research in this area as it 
relates to assistive technology intervention is evident.  With this in mind, the purposes of this 
study were both substantive and methodological.  They were: 1.  to examine changes in quality 
of life measures that parallel changes in functional mobility, 2.  to investigate changes in strength 
and fatigue accompanying a change in primary means of mobility in persons with MS, and 3.  to 
develop hypotheses for more definitive and refined research design and methods.  Through this 
study, we hope to provide individuals with MS and their clinicians with information that can 
prove to be helpful in making a more informed decision regarding mobility device selection, 
ultimately leading to an increased quality of life.  Quality of life has been defined many different 
ways, and yet, most definitions incorporate the match between one’s life experiences and their 
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life expectations.  For an individual with mobility impairments, an appropriate wheeled mobility 
device, that allows them to perform and participate in the activities important to them, has the 
potential to close the gap between what a person experiences and what they expect out of life.   
We hypothesize that a transition to wheeled mobility will lead to a small to negligible rate of 
decline in ambulatory ability and muscle strength.  However, the decrease in subjective fatigue 
and the increased ability to participate in everyday activities allowed through the used of a 
wheelchair or scooter will result in an overall increased quality of life.   
 
 
3.3.METHODS  
 
3.3.1. Participants 
We aimed to recruit a total of 20 people from assistive technology clinics throughout the 
Pittsburgh region.  Subjects were included in this study if they: 
• Had MS as diagnosed by the McDonald criteria (McDonald et al, 2001) 
• Were able to ambulate as their primary means of mobility (EDSS ≤ 7.0 (able to ambulate 
at least 5m with bilateral assistance),  
• Did not already own a wheelchair or scooter.  
• Had been referred for a wheelchair (power or manual) or scooter and  
• Were between the ages of 18 and 65 years 
Subjects were excluded from this study if they: 
• Had any other diagnosis besides MS causing a decline in mobility status 
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• Had significant depressive symptoms (CESD>13 (Radloff, 1977) or cognitive 
impairment (MMSE<26) (Folstein et al, 1975) 
• Had experienced a MS exacerbation within 3 months prior to inclusion  
• Had a history of a hernia in the last 2 months 
• Were hospitalized or had a surgery within the last two months 
• Were pregnant 
The study was approved by the Veterans Administration Pittsburgh Healthcare System (VAPHS) 
Investigational Review Board (IRB), and all participants provided written informed consent prior 
to inclusion in the study.   
 
In addition, an investigator at the Denver, CO Veterans Health Administration (VHA) 
wheelchair clinic was trained to collect study data.  The protocol conducted in Denver mimicked 
exactly the protocol performed at the Pittsburgh, with exception of wheelchair mobility 
monitoring using the datalogger (described below).  All testing took place at either the Pittsburgh 
Highland Drive Veterans Health Administration Medical Center (VAMC), or the Denver 
VAMC.  Subjects were offered transportation to the testing site, since it has been shown that 
transportation may be the factor of greatest importance in improving participation (Schwartz and 
Fox, 1995).   
   
3.3.2. Study design 
A quasi-experimental, longitudinal design was used, and all subjects served as their own controls 
(Figure 2).  The first visit, V1, occurred at or near the time in which the subject was prescribed a 
power wheelchair or scooter.  The second visit, V2, was at the time of assistive technology 
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delivery, which typically occurs an average of two to four months after the initial testing phase.  
Changes occurring during the interval between V1 and V2 served as a control for those that 
occurred after the transition to the alternative mobility device.  Subjects were asked to come in 
for the third visit, V3, at a time equivalent to the time between V1 and V2, +/- 4 weeks (Figure 
2).  All data collection was the same over the three visits, unless precluded by exclusion criteria.   
Figure 2 Testing longitudinal design 
 
    2-4 mo. time interval              2-4 mo. time interval 
V1___________________V2___________________V3 
     Initial           2nd Baseline    Intervention 
 
We attempted to recruit a total of 20 subjects with MS from both the Center for Assistive 
Technology in Pittsburgh, PA, as well as the Denver VAMC wheelchair clinic.  Based on means 
and standard deviations of the SF-36 (Trefler et al, 2004), and non-published research completed 
at our laboratory on changes in social participation as measured by the CHART, we expected to 
have 80% power to detect significant differences in quality of life and participation at an alpha of 
0.05.  We expected to see large increases (change in score by 15 points) in the SF-36 over time, 
and we expected to see decreases of 6-10% in muscle strength over time after the intervention 
based on the work of Kent-Braun and Bloomfield (Kent-Braun et al, 1997; Bloomfield, 1997).   
 
3.3.3. Protocol 
In order to control for external variability that may have contributed to measurement error, the 
room temperature for testing was maintained at 70°F +/- 3°, and all testing began between 9:30 
am and 11am.  First visit testing took approximately 4 hours, and subsequent visits took between 
2.5-3.5 hours.   
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3.3.3.1. Functional Testing 
Each subject performed the timed 8 meter walk test (T8).  For this test, subjects were asked to 
ambulate 8 meters on a tiled surface as fast as they were able, using whatever type of ambulation 
aid they felt was necessary.  Subjects were encouraged to walk with the least amount of 
assistance possible.  They were then asked to repeat this ambulation trial, this time walking the 8 
meters at their own normal walking speed (NWS-T8).  Again, they used whatever type of 
ambulation aid necessary.   
 
Subjects were also asked to propel an ultralight wheelchair the same 8 meter distance, and the 
time in which they completed this task was recorded.  The ultralight wheelchair was provided by 
the laboratory, and was adjusted so that each individual had approximately one inch between 
each side of their hips and the wheelchair when sitting.   
 
3.3.3.2. Maximal Voluntary Contraction 
Prior to strength testing, subjects’ blood pressure was recorded.  Any individual with a systolic 
blood pressure > 160, diastolic blood pressure > 90 or heart rate <50 or >100, was excluded from 
strength testing.  Strength testing was performed using the Biodex 3 (Biodex Medical, Shirley, 
NY).  Subjects were positioned in the Biodex such that the joint under consideration was aligned 
with the center of rotation of the system.  For each joint tested, subjects were asked to perform 
up to 10 sub-maximal repetitions of the test in order to become familiar with the procedure.  
After 3 minutes of seated rest, subjects were asked to perform two five-second maximal 
isometric repetitions, with a five-second rest in between each repetition in order to obtain a 
maximal voluntary contraction (MVC).  Subjects were asked to watch the computer screen 
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during testing for visual feedback, and verbal feedback was scripted.  MVC testing was 
performed in the following order: 
• Knee extension at 90°- subject in sitting, 90° hip flexion 
• Knee flexion at 90°- subject in sitting, 90° hip flexion 
• Ankle dorsiflexion (DF) in neutral dorsiflexion/ plantarflexion- subject in sitting, hip in 
95° hip flexion, 15° knee flexion with thigh supported 
• Hip flexion at 90°- subject in sitting 
• Elbow flexion at 90°- upper extremity in approximately 45° scaption 
• Elbow extension at 90°- upper extremity in approximately 45° scaption 
Between each muscle testing, subjects were given 2-3 minutes of rest.  The peak torque (PT) was 
calculated for each of the six muscles tested as the mean peak torque production over two 
repetitions.  The total PT (PTtotal) was used in the analysis, and was calculated as the summed 
total PT of each of the muscles tested. 
 
3.3.3.3. Questionnaires 
After completing MVC testing, subjects were asked to complete a series of four forms in 
Microsoft Access format.  These forms included an intake form, which asked information 
regarding the subject’s date of diagnosis, primary means of mobility, ability to ambulate, and 
number of falls in the last month, the Short Form-36 (SF-36) Health-related quality of life 
questionnaire (Ware et al, 1993), the Craig Handicap Assessment Reporting Technique 
(CHART) (Whiteneck et al, 1992) which measures participation in daily activities, and the 
Modified Fatigue Impact Scale (MFIS) (Fisk, 1994a; Fisk, 1994b), which measures how fatigue 
has affected the individual’s ability to perform daily activities over the past week.  There are ten 
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outcome variables from the SF-36 including: 1. physical functioning (PF)  2. social functioning 
(SF),  3. role limitations physical (RP),  4. bodily pain (BP),  5. general medical health (GH),  6. 
mental health (MH),  7.  role limitations emotional (RE),  8.  vitality (VT),  9. composite physical 
health status (PCS) and  10. composite mental health scores.  In a previously described study, we 
have shown that, when compared to published norms, individuals with MS who are about to 
transition in their primary means of mobility have markedly decreased quality of life scores in 
the domains of the SF-36 that measure physical, and not mental functioning (Ambrosio et al, in 
review).  Therefore, for this study, we considered only the PF, SF, RP, BP, GH, and PCS.  The 
three outcome variables considered in the CHART were the physical independence score, the 
mobility score and the occupation score.  Subjects who were familiar using computers completed 
the forms independently, with an investigator observing the procedure.  Otherwise, the 
investigator asked the subject the questions and filled out the forms on the computer.  
Completing all questionnaires took between 45minutes to 1 hour. 
 
3.3.3.4. Static Fatigue Testing 
After completing the questionnaires, the subjects were asked to return to the Biodex and perform 
a 30-second sustained maximal isometric contraction of the same muscles as tested in the MVC 
trials, and in the same order.  Joint positions in which the subjects were tested during the MVC 
trials were recorded so that the same positions were used for the static fatigue testing trial.  
Again, subjects were given 2-3 minutes of rest in between each muscle testing.  The static fatigue 
index (SFI) for each muscle was calculated based on a model proposed by Schwid, et al (1999) 
(Figure 3).  In this model, the time to generate a maximal contraction is removed from the 
equation (Tmax), and from the remaining time, the ratio of the area under the force versus time 
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curve (AUC) over the theoretical area if the individual were able to maintain a maximal 
contraction (Fmax) for the remainder of the 30-second trial.  The SFI is then representative of the 
area between these two curves, area ‘b’ in Figure 3, given as a percentage.  The equation for SFI 
is given as:  
Equation 1:  SFI = 100% x [1-(AUC/[Fmax * (30-Tmax)])] 
Figure 3 Force vs. Time Curve (Adapted from Schwid et al, 1999) 
     Fmax               b 
 
 
 
 
 
 
3.3.3.5. Electromyography 
During strength and static fatigue testing, the Noraxon MyoSystem 1200 EMG system (Noraxon; 
Scottsdale, AZ) was synchronized with Biodex measurements to concurrently collect surface 
EMG data.  Bipolar disc-shaped surface electrodes were placed over the dominant side 
quadriceps, tibialis anterior, biceps and triceps as described by Basmajian (Basmajian, 1980).  
Alcohol was used to cleanse the skin prior to adhering the electrode, and the inter-electrode 
distance was approximately 1 cm.  The EMG signal was sampled at a rate of 1000 Hz.  During 
the static fatigue trial, a power density spectrum was obtained by a Fast Fourier Transformation 
using a 2-second data window.  We then took an average of the power spectral slope across all 
four muscle groups tested (PStot.) in order to quantify muscle fatigue.  
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3.3.3.6. Mobility Monitoring 
After completing V1 testing, each subject was given a pedometer, and they were asked to record 
the pedometer reading each night.  Subjects who completed visits V2 and V3 were once again 
provided with a pedometer. In addition, we mounted our data logger on their wheelchair or 
scooter.  The data logger provides total distance traveled in the wheelchair and the speed at 
which they are traveling (Spaeth et al, 2000).  Subjects were instructed to disregard the 
pedometer and the datalogger, and continue with their daily activities as normal.  Together with 
the pedometer data, we could get an idea of how active the subject is while walking and using 
their wheelchair.  We were also able to record how much the individual is actually using their 
new wheelchair.  At the end of one week, investigators visited the subject’s home to retrieve the 
data logger and the pedometer. 
 
3.3.4. Statistical Analysis 
Gender was described using frequency counts.  Means +/- standard deviations were calculated 
for continuous data including age, and years since diagnosis.  Given the difficulties we 
encountered with subject recruitment, only descriptive statistics for testing variables are 
presented.   
 
3.4.RESULTS 
 
3.4.1. Participants 
Initial Pittsburgh VA IRB approval for recruiting subjects was obtained in July, 2003.  
Recruitment was solicited via fliers, pamphlets, and by contacting local rehabilitation clinics and 
MS support societies.  From July to September, we were unable to recruit any ambulatory 
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subjects with MS.  Therefore, in September 2003, we submitted an IRB modification in which 
we intended to recruit not only ambulatory subjects with MS who were transitioning to the use of 
a wheeled mobility, but also individuals with MS who were transitioning from a manual 
wheelchair to the use of a power wheelchair or scooter (Figure 4).   
Figure 4 Patterns of mobility transition considered 
 
Ambulation     Manual Wheelchair 
Ambulation      Power Wheelchair or scooter 
Manual Wheelchair    Power wheelchair or scooter 
 
The first subject was consented and tested in October, 2003.  At the time of the yearly review in 
March, 2004, only three subjects with MS who were transitioning in their primary means of 
mobility had been recruited.  Therefore, in the yearly review, we submitted a modification to 
include all individuals with chronic disorders who were transitioning in their primary means of 
mobility, either from ambulation to the use of any type of wheeled mobility, or from the use of a 
manual wheelchair to the use of powered mobility.  Chronic disorders considered included all 
those diagnoses leading to a decline in mobility status, not including those resulting from cardiac 
conditions, orthopedic, or other conditions that would preclude strength testing.  All individuals 
needed to have a prescription for their first powered mobility.  In total, between July 2003 and 
April 2005, 13 subjects were recruited.   
 
Of all subjects recruited, six of the subjects were excluded or withdrawn from the study.  The 
first individual was withdrawn after her first visit because she was denied the new wheelchair 
that was prescribed, and she decided she no longer needed to transition in her primary means of 
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mobility.  The second individual, who was transitioning from the use of a manual wheelchair to 
the use of a powered wheelchair, was excluded because she later told us that she had a scooter 
that she had been using quite regularly, since before the time of her 1st visit.  Because she did not 
meet the inclusion criteria, neither her V1 nor V2 data were included in the analysis.  The third 
individual was excluded from the study because, after the first visit, the subject used the 
reimbursement for participating in the study to fix an old scooter he had.  Within two weeks of 
completing his first visit, he was using the scooter as his primary means of mobility outside of 
the home.  The fourth individual scored 22 on the MMSE, and, therefore, did not meet inclusion 
criteria.  Finally, the fifth individual was withdrawn from the study because she never returned 
our follow-up calls.  Therefore, in total, 13 individuals completed the informed consent for 
participation in the study, 11 individuals’ data were considered for V1, 6 for V2, and 3 for V3 
(Figure 5). 
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Figure 5 Flow chart of participation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individuals seen at CAT
between November, 2003
and April, 2005 
n= 702 
Individuals contacted to
participate in study 
n= 23 
Not interested in participating in study 
n= 5 
Individuals scheduled for
testing 
n= 18 
Consented into study 
n= 13 
Did not show up for testing 
n= 5 
Participated in V1 testing 
n= 12 
Individuals who signed
CAT registry 
n= 233 
Did not meet inclusion/ exclusion
criteria 
n= 1 
Did not sign CAT registry (not
contacted to participate in study) 
n= 469 
Not eligible for study/ Could not be
contacted/ no info 
n=  211 
Withdrawn from study 
n= 5 
 
 
Longitudinal data collection 
n= 7 
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The study protocol was submitted to the Denver IRB was accepted in January, 2004.  From this 
date to April of 2005, 5 subjects were consented to the study.  However, only one was included.  
This subject completed both V1 and V2 testing.  Of the other four that were consented, two of 
the subjects had high blood pressure prior to beginning testing, and did not continue further, and 
the other two subjects did not meet the MMSE criteria, and were excluded from the study.  
Denver data is not included in the analysis. 
 
3.4.1.1. Subject Demographics 
Nine females and two males participated in this study.  The average age of the participants was 
49.9 +/- 7.1 years (range: 37.5-63.3 years).  Nine of the 11 subjects had MS as diagnosed by a 
neurologist, one had osteoarthritis, and one had degenerative disk disorder as their major 
diagnosis resulting in mobility impairment.  The average time since diagnosis was 12.8 +/- 7.2 
years (range: 7 months to 20 years).  Three of the individuals, two of which were non-
ambulatory, reported having a manual wheelchair at the time of inclusion in the study.  One 
individual had an EDSS score of 5.0 (Ambulatory without aid for about 200 meters. Disability 
impairs full daily activities), 7 individuals had an EDSS score of 6.0 (Intermittent or unilateral 
constant assistance (cane, crutch or brace) required to walk 100 meters with or without resting), 
one had a score of 6.5 (Constant bilateral support (cane, crutch or braces) required to walk 20 
meters without resting), and the remaining 2 had an EDSS score of 8.0 (Essentially restricted to 
bed, chair, or wheelchair, but may be out of bed much of day; retains self care functions, 
generally effective use of arms).  Eight of the 11 subjects who participated in this study had 
fallen at least once in the last month (range: 1 to “>20”). 
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After completing V1, regular phone calls were made to subjects in order to have an idea of when 
they were scheduled to receive their new mobility device.  The second visit was then scheduled 
at or near the time of mobility device delivery.  For the five subjects who completed second visit 
testing, the average time in between V1 and V2 was 15.3 weeks +/- 4.1 (range: 11 weeks to 20 
weeks).  Four of the 5 subjects had MS.   
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Table 3 Description of subject participation and withdrawal 
Note:  Yellow highlighting indicates that the subject was withdrawn from the study. 
Subject # 
(transition) 
Diagnosis Visit 1 Visit 2 Visit 3 Comments 
1 
Amb- PWC 
MS 10/13/2003 03/03/2004 
(20 weeks) 
09/07/2004  
2 
Amb- scooter 
MS 11/06/2003 01/28/2004 
(12 weeks) 
04/29/2004 Ambulation to 
scooter 
3 
Amb-PWC 
MS 12/22/2003   Power wheelchair 
denied 
4 
MWC- PWC 
MS 05/13/2004 11/18/2004 
(27 weeks) 
 At second visit, 
informed us that she 
used both a manual 
wheelchair and a 
scooter before 
having a prescription 
for a power 
wheelchair. 
5 
Amb- PWC 
MS 05/19/2004   Decided not to get 
the power 
wheelchair. 
6 
MWC- PWC 
MS 05/20/2004 09/13/2004 
(20 weeks) 
 Manual wheelchair 
to power wheelchair.  
Power wheelchair 
was broken for 1 
month in between 
V1 and V2 
7 
MWC- PWC 
MS 06/02/2004   Used reimbursement 
money from V1 to 
fix an old scooter 
8 
MWC- PWC 
Post-polio 06/08/2004   Did not meet MMSE 
criteria. 
9 
Amb- PWC 
Osteoarthritis 08/18/2004   Has not returned 
phone calls 
10 
Amb- scooter 
Degenerative 
Disk Disorder 
09/22/2004 12/08/2004 
(11 weeks) 
02/24/2004 
 
 
11 
Amb- PWC 
MS 09/23/2004   Has not yet received 
wheelchair. 
12 
Amb- PWC 
MS 11/17/2004 03/29/2005 
(18 weeks) 
  
13 
Amb- PWC 
MS 01/27/2005    
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3.4.2. Protocol 
3.4.2.1. Functional Testing  
Two individuals who participated in this study were non-ambulatory.  Therefore, at V1, nine 
individuals, seven with MS, completed the T8 with an average time of 12.6 +/- 4.8 seconds 
(0.63m/s).  The normal walking speed trial, (NWS-T8) average time to complete the T8 was 14.1 
+/- 3.7seconds (0.57m/s). 
 
The average time to complete the 8 meter wheelchair propulsion trial was 12.7 +/- 4.8 seconds 
(0.63m/s).  One of the 12 individuals did not complete the wheelchair propulsion trial because 
the laboratory did not have an appropriately fitting ultralight wheelchair.  All three individuals 
who completed V1, V2 and V3 completed the ambulation trials each time.  Results are shown in 
Table 4 and Figure 6.   
 
Table 4 Time to complete T8 (seconds) over V1, V2, and V3  
Subject 
# 
 
V1 
(sec) 
V2 
(sec) 
V3 
(sec) 
% 
Change 
 V1-V2 
% 
Change 
V2-V3 
1 
 
14.9 14.0 13.75 -6 -2 
2 
 
6.41 7.03 7.72 +13 +9 
3 
 
7.31 8.4 7.34 +13 -13 
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 Figure 6 Timed 25 Foot Walk test over three visits, n = 3 
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Note: The average # of weeks between V1and V2= 14.3; average # of weeks between V2 and 
V3=17.0 
 
Since one of the individuals who returned for V2 was non-ambulatory, 4 individuals completed 
the T8 during their second visit.  The average time to complete the T8 was 10.9 +/- 3.7 seconds 
(0.73m/s).  The average time to complete the NWS-T8 was 12.8 +/- 3.1 (0.63m/s).  For the 
wheelchair propulsion trial, one individual requested not to perform the trial because she felt 
unsafe using the ultralight wheelchair secondary to decreased trunk stability.  Another subject 
did not complete the trial because the laboratory did not have a large enough ultralight 
wheelchair.  Finally, another subject did not complete the trial because of a protocol error.  
Therefore, two individuals completed the wheelchair propulsion trial during V2.  For these 
individuals, the average time to propel the wheelchair 8 meters was 11.41 +/- 3.01 seconds (0.70 
m/s) 
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3.4.2.2. Maximal Voluntary Contraction 
Initial strength measurements were completed for 6 subjects who completed the first visit testing.  
All 6 of these subjects had MS (see Table 5 for a summary of peak torques).  Four of the subjects 
had blood pressures in excess of the acceptable level, and, therefore, did not complete testing.  
One subject did not complete strength testing secondary to reported low back pain as a result of 
osteoporosis.  The average PTtotal for the subjects tested was 184.7 +/- 54.2. 
 
Table 5.V1 average peak torques in newtons (N) (n=6) 
Knee 
Flexion 
(N) 
Knee 
Extension 
(N) 
Ankle 
Dorsiflexion 
(N) 
Hip 
Flexion 
(N) 
Elbow 
Flexion (N) 
Elbow 
Extension 
(N) 
20.8 +/- 6.0 
 
66.1 +/- 32.0 12.2 +/-  4.9 42.7 +/-
16.9 
22.6 +/-  8.2 20.4 +/- 3.8 
 
Subjects who did not complete strength testing during V1 did not complete strength testing 
during V2.  This was the case for 2 of the 5 subjects who returned to complete V2.  In addition, 
one subject, who was able to complete strength testing during V1, had blood pressure 
measurements outside the acceptable range during V2, and therefore could not complete this 
portion of the testing.  Therefore, V2 strength testing was completed in 2 subjects.  For these 2 
subjects, the average was PTtotal 124.5 +/- 38.9. 
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Figure 7. Peak Isometric Strength 
Example progression of peak isometric strength 
over three visits
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Note:  The #  of weeks between V1 and V2= 12; the # of weeks between V2 and V3=13 Example 
progression of peak isometric strength over three visits for knee flexion (Knee Flex), knee 
extension (Knee Ext), ankle dorsiflexion (Ankle DF), hip flexion (Hip Flex), elbow flexion (Elbow 
Flex), and elbow extension (Elbow Ext), n=1 
 
3.4.2.3. Questionnaires 
Tables 6 and 7 display a summary of SF-36 and the CHART scores, respectively, for the V1 
subject testing scores.  A domain score of 100 is considered to be the level of performance of a 
typical, non-disabled individual.   
Table 6 Visit 1:  SF-36 summary scores for 10 domains: physical functioning (PF), social 
functioning (SF), role physical (RP), bodily pain (BP), general health (GH), and physical 
composite score (PCS), subjects n=11 
Variable PF SF RP BP GH PCS 
Subjects 
Mean +/- 
SD 
 25.9 
+/- 
27.5 
 51.1 
+/-
28.2 
22.7 
+/- 
36.1 
46.5 
+/- 
29.2 
39.0 
+/- 
30.4 
24.3 
+/- 
10.7 
General 
US 
population 
84 83 81 75 72 50 
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Table 7 Visit 1:  CHART summary scores for 3 domains: physical independence, mobility, and 
occupation scores, n=11. 
Variable Physical 
Independence 
Mobility Occupation
Mean +/-  
SD 
83.6 +/- 28.9 81.7 +/- 
24.6 
64.7 +/- 
39.2 
 
The average MFIS score for the V1 subjects was 13.3 +/- 3.0 (n=11) 
Tables 8 and 9 display a summary of SF-36 and the CHART scores for the V2 subjects.  
 
Table 8 Visit 2:  SF-36 summary scores for 10 domains: physical functioning (PF), social 
functioning (SF), role physical (RP), bodily pain (BP), general health (GH), and physical 
composite score (PCS), n=5 
Variable PF SF RP BP GH PCS 
Mean +/- 
SD 
17.0+/-
22.0 
67.5+/- 
34.9 
10.0+/- 
13.7 
44.6+/- 
33.4 
38.4+/- 
22.3 
23.0+/- 
8.8 
 
 
Table 9 Visit 2:  CHART summary scores for 3 domains: physical independence, mobility, and 
occupation scores, n=5 
Variable Physical 
Independence 
Mobility Occupation
Mean +/-  
SD 
83.8 +/- 32.1 71.6 +/- 
30.9 
83.4 +/- 
33.8 
 
The average MFIS score for the V2 subjects was 13.0 +/- 5.2 (n=5).  SF-36 and CHART scores 
for the V3 subjects are presented in Tables 10 and 11.   
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Table 10 Visit 3:  SF-36 summary scores for 10 domains: physical functioning (PF), social 
functioning (SF), role physical (RP), bodily pain (BP), general health (GH), and physical 
composite score (PCS), n=3 
Variable PF SF RP BP GH PCS 
Mean +/- 
SD 
21.7 
+/- 
7.6 
87.5 
+/-
12.5 
50.0 
+/- 
50.0 
51.3 
+/-
42.4 
44.0 
+/-
16.4 
29.2 
+/-
12.2 
 
Table 11 Visit 3:  CHART summary scores for 3 domains: physical independence, mobility, and 
occupation scores, n=3 
Variable Physical 
Independence 
Mobility Occupation
Mean +/-  
SD 
98.5 +/-  0.5 87.0 +/- 
16.1 
100.0 +/- 
0.0 
 
The average MFIS score for the individuals who completed V3 was 10.7 +/- 4.5 (n=3). 
Figure 8 is a representative graph of one subject’s rate of change in health related quality of life 
at baseline (between V1 and V2) and after intervention (between V2 and V3). 
 
 
 
Figure 8.SF-36 over three visits for Subject # 1 
SF-36 Outcome Variables- Subject #1
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Note:  The # of weeks between V1 and V2= 20; the # of weeks between V2 and V3= 27;  
Example graph for the progression of SF-36 domain scores, physical functioning (PF), social 
functioning (SF), role physical (RP), bodily pain (BP), general health (GH), and physical 
composite score (PCS), over the three visits for subject #1 
 
Taken together with datalogger mobility monitoring data, this subject used her new mobility 
device almost daily, between 5-6 days out of the week, in addition to maintaining daily 
ambulation.  On the other hand, Figure 9 represents another subject’s rate of change in health-
related quality of life over the 3 visits.   
 
Figure 9. SF-36 over three visits for Subject #2 
SF-36 Outcome Variables- Subject #2
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Note:  The # of weeks between V1 and V2= 12; the # of weeks between V2 and V3=13; Example 
graph for the progression of SF-36 domain scores, physical functioning (PF), social functioning 
(SF), role physical (RP), bodily pain (BP), general health (GH), and physical composite score 
(PCS), over the three visits for subject #2 
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This subject reported rarely using her new mobility device, and datalogger monitoring showed 
she only used the chair approximately 3 days a week.   
 
3.4.2.4. Static Fatigue Testing 
All individuals who completed the strength testing portion of the protocol completed the static 
fatigue testing.  Variable summary scores are displayed in Tables 12, 13 and 14 for visit 1, 2 and 
3, respectively.   
  
 
Table 12 Visit 1: Static Fatigue Index (SFI) means +/- standard deviations for knee flexion, knee 
extension, ankle DF, hip flexion, elbow extension, and elbow flexion, n=6 
SFI 
variable 
Knee 
Flexion 
Knee 
Extension 
Ankle DF Hip 
Flexion 
Elbow 
Extension 
Elbow 
Flexion 
Mean +/-  
SD 
37.5% +/- 
12.9 
21.3% +/- 
2.5 
87.1% +/- 
13.7 
53.1% 
+/- 23.4 
22.3% +/- 
11.9 
30.7% 
+/- 10.5 
 
 
Table 13 Visit 2: Static Fatigue Index (SFI) means +/- standard deviations for knee flexion, knee 
extension, ankle DF, hip flexion, elbow extension, and elbow flexion, n=2 
SFI 
variable 
Knee 
Flexion 
Knee 
Extension 
Ankle DF Hip 
Flexion 
Elbow 
Extension 
Elbow 
Flexion 
Mean +/-  
SD 
56.9+/- 2.1 8.75 +/- 1.5 51.4 57.95 +/- 
54.7 
39.9 +/- 8.0 50.1 
 
   
Table 14. Visit 3: Static Fatigue Index (SFI) means +/- standard deviations for knee flexion, knee 
extension, ankle DF, hip flexion, elbow extension, and elbow flexion, n=1 
SFI 
variable 
Knee 
Flexion 
Knee 
Extension 
Ankle DF Hip 
Flexion 
Elbow 
Extension 
Elbow 
Flexion 
Mean  46.5 9.1 90.4 90.4 3.5 3.5 
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Figure 10 Example graph for the progression of static fatigue index of the knee flexors, knee 
extensors, ankle dorsiflexors (DF), hip flexors, and elbow extensors for subject #2 
Example graph for the progression of static 
fatigue index, subject #2
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Note:  Data missing for elbow extensor SFI at V2.  Therefore, elbow extensors are not graphed. 
3.4.2.5. Electromyography 
 
Table 15 demonstrates single subject muscle fatigue data as determined by power spectal density 
analysis, obtained through a fast-fourier transformation.  This subject transitioned from 
ambulation to the use of a scooter.  Elbow flexor and elbow extensor muscle fatigue increased 
after mobility device intervention.  However, lower extremity muscles, knee extensors and ankle 
dorsiflexors, actually showed a decrease in median frequency, and therefore, a decrease in 
muscle fatigue after mobility device intervention between V2 and V3.    
 
Table 15 Example progression of Power Spectral Density across three visits, n=1 
Muscle V1 Slope (Hz/ sec) V2 Slope (Hz/ sec) V3 Slope (Hz/ sec) 
Knee extensors 0.16 0.18 -0.04 
Ankle 
dorsiflexors 
-0.31 -0.87 -0.42 
Elbow flexors  -0.11 -0.28 -0.86 
Elbow extensors -0.41 -0.27 -0.37 
PStot -0.17 -0.31 -0.42 
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3.4.2.6. Mobility Monitoring 
All ambulatory subjects (N=9) completed pedometer mobility monitoring for the seven days 
following V1.  The average recorded pedometer steps/day was 1813.1 +/- 765.9 (range: 240.0-
2744.4 steps/ day).   
 
For the two individuals who were non-ambulatory at the time of inclusion into the study, 
dataloggers were mounted on their manual chairs after V1 to get an idea of their daily activity.  
After one week of monitoring daily wheelchair use, the average daily distance traveled was 
79.7m and 950.7m for each of the subjects.  When considering the total distance traveled over 
one week, these two individuals traveled 557.9 m and 6655.0 m at an average speed of 0.12 and 
0.21m/sec, respectively.  
 
 
3.5.DISCUSSION 
 
MS has the potential to severely debilitate and functionally impair any individual.  Hopefully, the 
devastating effects of MS will one day be prevented.  Until then, efforts should be focused on 
improving the individual’s everyday functioning, and ultimately, their quality of life.  It was the 
aim of this research to provide initial evidence of the physical and psychosocial changes that are 
commonly seen as they transition in their primary means of mobility.  We intend for this 
information to be useful to consumers and their clinicians in the selection and timing of mobility 
device prescription.  Furthermore, we believe an account of some of the difficulties encountered 
with conducting this type of longitudinal mobility research in this type of population will be 
useful for designing and implementing similar future research designs.   To the best of our 
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knowledge, ours was the first study of its type to attempt to provide some indication of what 
individuals can expect as they transition to an increased reliance on AT.   
 
3.5.1. Subject Recruitment 
The difficulties we encountered regarding subject recruitment was not unique to our study, and, 
therefore, was not surprising.  Subject participation rates in clinical trials have been shown to 
range from 3-20% (Chang et al, 2002).  Studies have investigated the characteristics of 
individuals who are willing to participate in clinical trials.  Such characteristics included: 
wanting to get the best available care, the belief that participation in the study would help fight 
their illness, and the fear that their condition would get worse without treatment (Schwartz and 
Fox, 1995).  Therefore, according to these studies, it is likely that individuals were not highly 
motivated to participate in this study, since they received no direct benefit or therapeutic 
intervention.  
Another reason for difficulty in recruiting subjects for this study is because of the strict 
inclusion/exclusion criteria.  Not only were there ten different inclusion/ exclusion criteria, but 
furthermore, individuals had to be recruited into a narrow window of time after receiving a 
prescription for a new wheeled mobility.  This introduced a number of issues regarding subject 
inclusion into the study, including scheduling conflicts with work, school, and taking care of the 
children.  Furthermore, because inclusion into the study needed to take place at or near the time 
of mobility device prescription, when many individuals were facing issues of acceptance of their 
disease progression.  As previously mentioned, for those unfamiliar with regular AT use, a 
wheelchair or scooter may represent increasing disability and decreased independence.  
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Therefore, psychosocial factors may have also limited individuals from being willing to 
participate in the study.   
 
In addition to the difficulties we encountered with subject recruitment, subject attrition was very 
high (50%).  Two individuals were ultimately withdrawn because they decided they no longer 
needed to transition to wheeled mobility.  The relapsing-remitting component of MS contributes 
to much of the variability in symptom presentation for individuals.  As individuals’ symptoms 
become inactive, they may feel they no longer need to transition to the use of a wheelchair or 
scooter.  However, this is likely to be a temporary resolution of symptoms, and the individual 
may find him/herself in a position of needing the mobility device in the near future.   
Finally, we anticipated that the time of wheelchair delivery would range between two months 
and four months.  However, for the six subjects who participated in V2, the average delivery 
time was almost 17 weeks.  This does not include two individuals who are still included in the 
study, who applied for a new wheelchair 5 and 7 months ago, and have still not received their 
new mobility device.  Interestingly, in a study by Jedeloo et al, (2002) authors found that 
delivery time was an important factor in explaining the level of satisfaction of individuals 
receiving a new wheelchair.  Increasing the time between follow-up visits increases the 
likelihood for subject withdrawl. 
 
3.5.2. Functional Testing 
According to Lerner-Frankiel et al (1986), 1.2 m/s can be considered a functional walking speed.  
Cross-sectional analysis of ambulatory ability in individuals who completed V1 testing revealed 
that these individuals, when asked to walk as fast as they are able, still do not reach functional 
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walking speeds.  In fact, their mean velocity was just over half as fast as what is considered to be 
functional, both when asked to ambulate as fast as they are able, and when they walked at their 
normal walking speed.   
 
Despite the fact that these individuals are not functional ambulators, antecdotal evidence has 
shown that individuals often resist the transition to wheeled mobility as long as possible, with the 
belief that relying on a wheelchair will increase the rate of decline in their ambulatory ability.  
That is, they feel that if they no longer rely on ambulation as their primary means of mobility, 
they will lose what walking ability they have.  While we were only able to collect longitudinal 
data on 3 subjects, our data indicates this is not likely to be the case.   
 
Schwid et al (2000) showed that a change of 20% or greater in the time to complete the T8 is 
needed to consider there to be a functional change in ambulatory ability.  For the three subjects 
who completed the T8 over all three visits, the average change in time to complete the T8 
between V1 and V2 was 11%, and the average change in the time to complete the T8 after 
mobility device intervention (between V2 and V3) was 8%.  Therefore, there was not a 
functional change in ambulatory ability, even after individuals transitioned to primarily the use 
of a power wheelchair for mobility.  Although this is only preliminary data, with a small sample 
size, it does support our original hypothesis that a transition to the use of a wheelchair will not 
lead to a clinically significant decrease in ambulatory ability.  Further research should be done to 
more conclusively describe the change in functional ability after the transition in primary means 
of mobility.  This information could prove to be very valuable to individuals and clinicians when 
faced with mobility decisions.   
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When considering the manual wheelchair propulsion trial, individuals tested were not able to 
propel a manual wheelchair at a functional speed, and propelled an average of 0.63 m/s.  This 
measure is limited by the fact that none of these individuals tested had experience propelling 
manual wheelchairs.  Therefore, their propulsion speed might have increased if they were 
experienced manual wheelchair users.  On the other hand, these findings are consistent with the 
findings of Fay et al, (2004), that showed that manual wheelchair users with MS, when asked to 
propel a manual wheelchair at their normal propulsion speed, pushed their wheelchairs at an 
average speed of 0.67 m/s.  
 
The typical clinical progression of mobility intervention moves from ambulation to some type of 
ambulation aid to the use of a manual wheelchair, and finally, the use of a power wheelchair as a 
last resort.  Our results reveal that the transition to the use of a manual wheelchair in chronic 
disorders may not always be the optimal choice of wheeled mobility when the use of walking 
aids fail, since these individuals are not functional wheelchair users.  It is possible that the direct 
transition to the use of powered mobility may prove to result in better functional outcomes for 
this population.  This is an important area of investigation for future studies.     
 
3.5.3. Maximal Voluntary Contraction 
Comparisons may be made in the lower extremity strength of individuals with MS who are about 
to transition in their primary means of mobility with reported lower extremity peak torques of 
individuals categorized as “fallers”.  Gehlsen & Whaley (1990) and Whipple, et al (1987) both 
showed that a significant difference exists in the lower extremity strength of elderly individuals 
classified as “fallers” or “non-fallers”.   
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In our study, individuals with MS who are waiting to receive a new mobility device had even 
lower knee extension, knee flexion, and ankle dorsiflexion peak torques (66.1N, 20.8N, and 
12.2N respectively) than individuals classified as “fallers” from Whipple et al (1987).  In fact, 
when our subjects were asked whether or not they had fallen in the last month, all but two of 
them said they had fallen at least once.  One individual reported having fallen over twenty times.  
Taken together, this data indicates that many individuals with chronic disorders who are about to 
transition to the use of wheeled mobility are already at high risk for falls.  It can be argued that 
these individuals should have considered a transition to a wheeled mobility at an earlier stage in 
order to prevent the risk of injury and further impairment.  Future research should seek to 
identify benchmarks that would alert clinicians of the need to consider a transition to wheeled 
mobility in individuals with MS.   
 
We were unable to collect sufficient longitudinal data across the three visits to make a statement 
about whether or not declines in strength are accelerated by the transition from ambulation as a 
primary means of mobility to primarily the use of wheeled mobility.  Only one subject completed 
strength testing for all three trials. However, for this individual, in all muscles except the ankle 
dorsiflexors, muscle strength actually increased after a transition to the use of a scooter.  This 
supports our hypothesis that a change in the primary means of mobility will not necessarily lead 
to an increase in the rate of decline in muscle strength.   
 
It has been shown that static fatigue is not significantly associated with strength of the same 
muscles (Schwid et al, 1999), and therefore, this was another important data point to collect.  
This is especially true given the fact that it is fatigue that so commonly interrupts participation in 
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daily activity in persons with MS (Krupp et al, 1988).  At V1, our subjects showed mean declines 
in motor output between 21.3% for the knee extensors, and 87.1% for ankle dorsiflexors.  While 
the SFI of the knee extensors in our population is comparable to that seen in the ambulatory 
subjects with MS from Schwid et al (1999) (28.0%), the SFI of the ankle dorsiflexors in our 
sample population is much greater than seen in their population (31.6%).  Future investigations 
should seek to determine how changes in lower extremity muscle endurance contribute to 
decreased function in this population, and how mobility device intervention affects motor 
fatigue.   
 
When we considered the change in the rate of muscle fatigue as determined by 
electromyography, for the subject tested over the three visits, we found that a transition from 
ambulation to the use of a scooter may not necessarily lead to decreased lower extremity muscle 
endurance, as might have been expected.  In fact, the subject tested actually demonstrated 
decreased knee extensor and ankle dorsiflexor fatiguability after transitioning to the use of a 
scooter.  However, this subject reported using her scooter infrequently.  Therefore, it is possible 
that her continued daily ambulation helped to maintain her lower extremity muscle endurance.  
Future studies should seek to describe more specifically the change in muscle fatiguability after a 
transition to wheeled mobility.     
 
3.5.4. Questionnaires 
It has been previously shown that transitioning to the use of powered mobility results in not only 
increased mobility, decreased pain and decreased discomfort but also quality of life benefits 
(Davies et al, 2003).  Another study showed that the transition to powered mobility enables self-
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controlled mobility and decreased dependence on others for assistance (Buning et al, 2001).  This 
ultimately results in improved social participation.   Furthermore, it has been shown that non-
ambulatory individuals with MS who rely on a combination of manual wheelchair and powered 
mobility participate in social activities almost twice as much as individuals who rely only on a 
manual wheelchair or who use a manual wheelchair, yet retain some ability to ambulate 
(Ambrosio et al, 2003).  These findings serve as a modest example of the impact AT can have in 
the lives of individuals with MS.  Our preliminary studies further support these findings.  
 
We hypothesized that, not only would a transition to the use of a wheelchair or scooter lead to 
minimal increases in the rate of muscle strength decline, but would also lead to an increase in 
health-related quality of life.  Ultimately, the increases in quality of life resulting from the 
mobility device intervention are a result of how often the individual is using their wheelchair.  
While we were unable to collect a sufficient number of longitudinal subject data to perform 
correlations, our preliminary data shows this to be the case.  In the individual who regularly used 
her wheelchair almost daily, an improvement in a majority of domain scores considered was 
evident.  On the other hand, for the individual who was prescribed a scooter, but reported not 
using it regularly after receipt, improvements in quality of life scores were not as evident.   These 
findings support our original hypothesis, and demonstrate a need for further investigation as to 
the correlation between mobility device use and improvements in health-related quality of life.   
 
3.5.5. Future studies/ considerations 
Although this study, to date, has collected fewer than expected subjects, it has highlighted the 
need for continued future research in the area of mobility transition in individuals with MS and 
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other chronic disorders, and has raised many important questions.  Why does there seem to be 
such a large percentage of undiagnosed high blood pressure in this population?  Why does it 
seem to take so long to receive a new wheelchair after it has been prescribed, and how does the 
variability of symptom presentation in a population such as MS affect the willingness of 
insurance companies to reimburse for assistive technology?  These are all topics rarely 
investigated, which, considering the widely acknowledged significance of mobility on quality of 
life in individuals with MS, lends to questions in and of themselves.  How many investigators 
desist from conducting longitudinal mobility research in populations such as MS because of 
difficulties and barriers as exemplified in our study?  Along these lines, how many grant 
agencies fail to fund longitudinal rehabilitation studies in populations with MS because they are 
well aware of the difficulties with subject recruitment and attrition?  As an example, one 
prominent organization specifically devoted to the cause of MS funds approximately 35 million 
dollars for research in MS.  A majority of research monies are allocated to more therapeutically-
based trials, with only approximately 1.8% granted to rehabilitation-based research.   
 
This study provides both substantive and methodologic information.  It suggests that individuals 
may be able to experience the quality life benefits associated with a transition in their primary 
means of mobility, without compromising muscle strength and ambulatory ability.  From a 
methodological perspective, the data demonstrate difficulties with recruitment for this type of 
population and obstacles in the retention of subjects throughout the study.  None-the-less, the 
benefits to be gained from this type of investigation may prove to be very valuable to clinicians 
and those who are considering a transition to wheeled mobility. 
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3.6.CONCLUSION 
 
There is much work that remains to be done to investigate the consequences of a transition in the 
primary means of mobility in people with MS, and in people with other chronic, progressive 
conditions.  Along these lines, studies should investigate strategies for improving patient 
participation in clinical trials such as this.  It is the responsibility of investigators to document 
and try to address barriers to recruitment in this population, as we have done here.  This would 
help to evaluate more efficiently the efficacy of treatment interventions and allow for faster 
translations of research from the laboratory to the clinic.  
 
This investigation provided preliminary data to test the model we predicted.  We believe that 
many individuals with MS are delaying a transition in their primary means of mobility because 
of a fear that an increased reliance on wheeled mobility may result in decreased independence 
and an increased deconditioning.  We hypothesized that, while a transition to wheeled mobility 
may lead to an accelerated rate in the decline of strength and a decreased in ambulatory ability, 
these effects would be outweighed by an increase in quality of life and participation in daily 
activities.  Even with a modest sample size, we found a tendency that individuals retained 
functional ambulatory ability as well as muscle strength and endurance, while concomitantly 
experiencing improvements in psychosocial parameters.  Future research should seek to solidify 
these findings, and relay them to populations such as MS who are often faced with difficult 
decisions regarding mobility transition.  This type of research has the potential to empower 
individuals by allowing them to make more informed decisions while having a clearer picture of 
what they can expect after a transition in their primary means of mobility.   Researchers should 
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confront the research design and recruitment difficulties, recognizing the importance of this area 
of investigation. 
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4.1.ABSTRACT  
 
Background:  Individuals with MS generally report a lower level of satisfaction with their 
mobility device when compared to individuals with SCI.  Given the association between mobility 
and quality of life in this population (Aronson, 1997), this may help to explain the disparity in 
overall health-perceived quality of life.  The purpose of this study was to: 1.) investigate the 
demographic differences between individuals with MS who are issued a wheelchair through the 
Veterans Health Administration (VHA) and 2.) describe the differences in wheeled mobility 
prescription within the VA for these two populations.  Methods: The VHA National Patient 
Care Database and the National Prosthetics Patient Database were merged to obtain demographic 
and wheelchair distribution information for all veterans with SCI and MS in 2000 and 2001.  
Results:  7076 veterans with SCI or MS received wheelchairs in the three years investigated, 
2154 of which had descriptive information about the type of wheelchair issued.  Of these 2154 
entries, we found that individuals with MS were less likely to receive the higher quality (based 
on weight and adjustability) wheelchairs (manual or power) when compared to individuals with 
SCI.  Discussion/ Conclusions:  The disparity in wheelchair prescription within the VA for 
these two populations may help explain the reported differences in AT satisfaction.   
 
 
 
 
Key Words: Wheelchairs, Multiple Sclerosis, Spinal Cord Injury, Assistive Technology 
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4.2.INTRODUCTION 
 
Approximately 13.1 million people use assistive devices in the US (LaPlante, 1992) for mobility, 
communication, and assistance with activities of daily living.  According to the US Technology-
Related Assistance of Individuals with Disabilities Act of 1988, Assistive Technology is defined 
as “any item, piece of equipment, or product system, whether acquired commercially off the 
shelf, modified, or customized, that is used to increase, maintain, or improve functional 
capabilities of individuals with disabilities” (USGov, 1998).  While technological advancements 
have allowed for a much more sophisticated array of assistive devices available, the effectiveness 
of the technology is only as good as the fit between the user and the technology to achieve the 
desired goal (Scherer, 1998).  The match between the person and the technology is dependent on 
the specific needs of the individual, based on functional limitations and disability, and the ability 
of the technology to compensate for these needs. 
 
Despite the increasing number of people using AT, and consequently, an increased need for 
appropriate matches between the user and the technology, there have been remarkably few 
studies investigating the process by which AT are issued to consumers.  With this in mind, the 
Veterans Health Administration (VHA) began tracking AT issued to all veterans, and making 
this database available to researchers.  The National Prosthetics Patient Database (NPPD) 
consists of all the orthotic, prosthetic and sensory devices distributed to veterans across the 
United States, including the first time the device was issued, any repairs and replacements.  This 
database was started in October of 1997, and became available to the research community in 
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October, 2000 (Downs, 2000).  This database provides valuable information regarding the 
distribution of assistive technology to veterans with a wide variety of diagnosis.   
 
According to SCI-Info-Pages (2005), there are 11,000 spinal cord injuries (SCI) each year in the 
US.  One study of 14 men and women with a newly acquired spinal cord injury (SCI) asked the 
subjects to rate their satisfaction with assistive technology one month after discharge from acute 
rehabilitation (Scherer and Cushman, 2000).  This study found that 64.3% of the respondents 
indicated that they were “Satisfied” with their assistive technology.  Cook et al (1981) showed 
that a majority of individuals with SCI studied 5 years post injury were functioning comparably 
to uninjured control counterparts in terms of life satisfaction and self-perceived adjustment. 
Cushman and Hassett (1992) studied 43 people with SCI 10 and 15 years post injury and 
collected data on subjects’ perceived quality of life.  They found that most subjects saw their life 
as comparable to, or somewhat better than that of age matched peers.  Siosteen et al (1990) 
concluded that people with adequate resources had lives as fulfilling as those of a matched group 
of non-disabled persons.  Again, however, these findings are diagnosis specific.  As the diagnosis 
and symptom presentation becomes more complex and unpredictable, such as is the case in 
multiple sclerosis (MS), it is likely that satisfaction of the user with the technology is more 
difficult to achieve.   
 
There is a large body of literature that focuses specifically on various aspects of quality of life in 
people with MS.  One study by Nortvedt and colleagues (1999) demonstrated that people with 
MS had markedly lower scores on all quality of life dimensions when compared to the general 
population.  Moreso, Lankhorst et al (1996) revealed a substantial deterioration of quality of life 
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measures in individuals with MS when compared to other patients with chronic illnesses.  
Correlates for a decreased quality of life in this population exist in the areas of fatigue, physical 
disability, neurological impairment, depression, and anxiety, to name a few (Merkelbach et al, 
2002; Janardhan, & Bakshi 2000; Fruehwald et al 2001).   
 
One correlation of particular interest has been seen between quality of life and mobility 
(Aronson, 1997; Everts and Karnilowski, 1996).  It has been reported that 85% of the patients 
with MS reported gait and motor disturbances as their chief complaint (Baum & Rothschild, 
1983).  One out of two persons with MS will require the assistance of another person for 
everyday mobility (Baum & Rothschild, 1983).  Among individuals with MS, 4% use crutches, 
12% use walkers or canes, and 40% use a wheelchair (Baum and Rothschild, 1983.  Of the 
individuals with MS who use a mobility device, it has been shown that 61% use a manual 
wheelchair, and only 8.2% used a power wheelchair (Finlayson et al, 2001).  However, because 
the database used in this study involved people in Canada with MS, which has a different system 
of healthcare and AT reimbursement, it cannot necessarily be generalized to the US.  Another 
study by Perks et al, reported that 59% of individuals in Scotland with MS state their current 
wheelchair does not meet their mobility needs (Perks et al, 1997). Wheeler and colleagues found 
that, when compared to other wheelchair users, individuals with MS are particularly skeptical, 
critical, and questioning about explanations given by health care providers regarding mobility 
selection (Wheeler et al, 1996).    
 
It is evident that the satisfaction of assistive devices by individuals with MS is very different than 
the satisfaction with assistive devices by individuals with SCI.  Although these two diagnoses are 
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very different, and symptom presentation may vary greatly between the two, once the decision to 
transition to a wheeled mobility device is made, all individuals are equally entitled to a 
wheelchair that will best meet their needs.  Based on clinical observation, we hypothesize that 
too many individuals with MS are using low-grade depot-style wheelchairs as their primary 
means of mobility.  This is particularly disturbing considering that depot wheelchairs are 
intended for temporary use only (for example, during a rehabilitation hospital stay)(Cooper 
1995), and have been shown to have markedly decreased half-lives, when compared to 
lightweight and ultralight wheelchairs (Fitzgerald et al, 2001).  
 
The first specific aim of this study was to characterize the demographic characteristics of 
individuals with MS and individuals with SCI who received a wheeled mobility device as 
represented in the VA NPPD.  The second specific aim was to compare the wheeled mobility 
devices issued to individuals with MS and individuals with SCI.  Specifically, we investigated 
the differences in the types of manual and power wheelchairs and scooters issued to these groups 
of veterans.  “Developing an understanding of what assistive devices these persons [with MS] 
possess, and what factors predict this possession may assist occupational therapists in thinking 
critically about how they work with this population and what service gaps may exist.”(Finlayson 
et al, 2001). 
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4.3.METHODS 
 
4.3.1. Study Design 
This study used a retrospective design to analyze two combined years of data, 2000 and 2001, 
from two different Veterans Health Administration (VHA) databases, the National Patient Care 
Database (NPCD) and the National Prosthetic Patient Database (NPPD).  These databases were 
merged to create a unique database with unique identifiers.  That is, individuals were included 
into the system only once, even if they received more than one wheelchair over the course of the 
two years investigated.  The NPCD was used to obtain demographic information for individuals, 
including date of birth, gender, race, and primary diagnosis.  The NPPD is a database that holds a 
record of the assistive devices issued to veterans.  For this study, we investigated NPPD 
information on the type of wheelchair issued and on the “create date” (see Table 16 for 
operational definitions of variables.)  Prior to obtaining the databases, an honest broker linked 
the two databases while maintaining patient confidentiality, as per the Health Insurance 
Portability and Accountability Act of 1996 (HIPPA) regulations.  In linking the data between the 
two databases, data sets were de-identified and patient IDs were scrambled.  A SAS statistical 
package was used to extract only those variables investigated from the original databases, and a 
new database, containing only information from veterans with MS or veterans with SCI, was 
created.  This study was approved by the VA Pittsburgh Healthcare System Institutional Review 
Board.   
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Table 16. Operational definitions of variables 
Variable Definition 
Age Age on the day that the wheelchair was ordered and put into the 
system 
Race According to six NPCD race categories: Hispanic Black, Hispanic 
White, American Indian, African American, Asian, and Caucasian, 
and a seventh category for “unknown.” 
Gender Male/ Female 
Type of 
Wheelchair 
Based on K-codes of medicare system for classification- See Table 
2 
Create Date Date that the wheelchair was ordered 
Diagnosis Primary diagnosis related to wheelchair use based on ICD-9 coding 
 
4.3.2. Data cleaning 
The process for cleaning the data of the merged database is described in Hubbard, S (Hubbard S, 
2004).  Briefly, the number of entries for each variable was based on the total number of entries 
minus missing values for that variable.  Age was calculated as the time in years between the 
create date and the birthdate.  If more than one diagnosis was recorded for a veteran, the 
diagnosis most likely to contribute to the use of a wheelchair was considered the primary 
diagnosis.  From these, all individuals with MS or a SCI were included in the dataset.  If a 
veteran had both a SCI and an MS diagnosis, they were grouped into the individuals with MS, 
since MS may be considered a type of spinal cord injury.  Individuals with SCI were identified if 
they were issued an ICD-9 code indicating a specific diagnosis with a SCI level, such as “C1-C2 
spinal cord injury.”  Both individuals with tetraplegic and paraplegic SCI were included in the 
SCI group.   
 
For type of wheelchair, authors used a new ranking system of eight wheelchair classes in order to 
simplify the medicare K-codes (HCFA Common Procedure Coding System (HCPCS).  Available 
at:  http://www.hcfa.gov/medicare/hcpcs.hmt) used to describe type of wheelchair issued taken 
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from Hubbard (2004).  The new ranking system was based on wheelchair function, weight, and 
adjustability.  Table 17 describes the grouping used to classify each of the wheelchair types.  If 
the same individual received a wheelchair in 2000 and/or 2001, only the wheelchair for the first 
year was used, in order to have a dataset comprised of unique entries.   
 
Table 17. Wheelchair classifications 
 
Code Type of 
Wheelchair 
Description 
 
K0001= manual wc- depot >36 lbs, non-adjustable; “depot” 
wheelchair 
K0002= manual wc- hemiplegia >36 lbs, non-adjustable, lower seat 
only; depot wheelchair 
K0003= manual wc lightweight 
M1 (1) 
<=36 lbs, non-adjustable; 
lightweight, depot wheelchair 
K004= manual wc lightweight M2 (2) <34 lbs, adjustable seat/back height, 
some adjustment in axle; high 
strength, lightweight; rehabilitation 
wheelchair 
K0005= manual wc ultralight M3 (3) <30 lbs., adjustable seat/back 
height/axle/camber; ultralight 
wheelchair 
K0010= power wc P1 (5) 
 
Non-adjustable, seat height only, 
standard weight non-programmable 
controls 
K0011= power wc 
 
P2 (6) Miscellaneous power wheelchairs 
K0014= power wc P3 (7) Custom power wheelchairs, other 
motorized wheelchair base 
E1230= scooter 
 
S1 (8) scooter 
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4.3.3. Statistical Analysis 
4.3.3.1. Specific Aim 1:  Demographic characteristics 
Descriptive statistics were used to compare demographic information between the two groups, 
including the number of entries per diagnosis.  Means +/- standard deviations were used to 
describe the age of each group, and frequency counts were used to describe gender and 
race/ethnicity.  All variables were tested for normal distribution.  An independent samples t-test 
was used to compare the ages of the two groups.   
 
In order to increase the power of our analysis, we compressed the race variable into two general 
groups, white and minority (Hispanic Black, Hispanic White, American Indian, Black, Asian and 
unknown).  A Chi-Squared analysis was used to compare the distribution of races among the two 
groups. 
 
4.3.3.2. Specific Aim 2:  Comparison of devices 
Frequency counts were used to describe the number of manual wheelchairs, power wheelchairs, 
and scooters issued to each group over both years.  Frequency counts were also used to describe 
the types of manual wheelchairs, power wheelchairs, or scooters issued.   
 
To investigate whether there is a significant difference in the type of wheelchair, manual, power, 
or scooter, issued to veterans with MS and veterans with a SCI, we used a one-way Chi-Squared 
analysis.  Groups were considered significantly different at p<0.001.  This p-value was selected 
as an indicator of significant difference between the comparison groups since the sample size for 
this study was large.  With a large sample size, there is an increased likelihood to observe 
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statistically, but not clinically significant differences.  We attempted to minimize this by using a 
strict cut-off point for significance.     
 
 
 
4.4.RESULTS 
 
According to our database, a total of 7,076 veterans with either a SCI or MS received 
wheelchairs between 2000 and 2001; however, because of missing data, we were only able to 
evaluate the types of wheelchairs issued to 2154 veterans.  The remaining 4922 veterans received 
wheelchairs, but we did not have enough information on the type of wheelchair they received to 
include them in the analysis.  Statistical analysis comparing race, gender, age and diagnosis of 
the individuals with incomplete information versus the entries used in our analysis revealed there 
was no significant difference between the two groups.   
 
4.4.1. Specific Aim 1: Demographic characteristics 
There was no significant difference between the group of data entries that were eliminated from 
the analysis because they did not have a classifiable wheelchair and the group that we analyzed.  
Of veterans considered, there were a total of 791 veterans with SCI, 90 of which had tetraplegia 
due to SCI.  There were 1363 veterans with MS. 
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4.4.1.1. Age   
Ages for all veterans included in our analysis who received wheelchairs in 2000 and 2001 ranged 
between 20.6 years and 100.2 years, with a mean age of 54.4 +/- 12.8 (Table 18).  An 
independent samples t-test indicated that there was a significant difference (p=0.000) between 
the ages of the SCI group and the MS group. 
  
4.4.1.2. Gender   
Males made up 92.3% of all individuals with either MS or SCI who received a classifiable 
wheelchair.  For each of the two groups, males also represented the majority of individuals who 
received wheelchairs (Table 18).   
Table 18 Age distribution for the two comparison groups, SCI and MS 
 
 
 
 
 
 
 
 
 
 
 
 
Group 
 
Age 
Mean +/- 
SD 
Gender 
% 
Male 
SCI 
(n= 791) 
 
52.8 +/- 
14.0 
 
98.0 
 
MS 
(n=1363) 
 
 
55.3 +/- 
12.0 
 
88.9 
4.4.1.3. Race   
White veterans made up 67.9% of veterans with SCI and 85% of veterans with MS.  There was a 
significant difference (p=0.000) in the race distributions of whites and minorities between the 
two diagnoses.   
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4.4.2. Specific Aim 2: Comparison of devices  
Individuals with a SCI received approximately the same number of manual wheelchairs as power 
wheelchairs (49.8% and 43.7%, respectively) (Table 19).  Scooters were the least frequently 
prescribed mobility device at only 6.4% of all devices issued to veterans with a SCI (Table 19).  
For veterans with MS, manual wheelchairs were the most commonly issued mobility device 
(44.7%), followed by power wheelchairs (33.7%), and finally scooters (21.6%).  A one-way Chi 
Squared analysis revealed there was a significant difference for each of the frequencies of 
manual wheelchairs, power wheelchairs and scooters issued to veterans according to diagnosis. 
 
Table 19 Compares the percentage of manual wheelchairs, power wheelchairs and scooters issued 
among the two groups 
 Number Manual 
Wheelchairs 
Number Power 
Wheelchairs 
Number 
Scooters 
 
Group 
 N % N % N % 
Total number 
wheelchairs 
SCI 
 
394 49.8 346 43.7 51 6.4 791 
MS 
 
609 44.7 460 33.7 294 21.6 1363 
Total 
 
1003 46.6 806 37.4 345 16.0 2154 
 
 
 
 
 
 
 
 
 
Note: Percentages given as percent of total number of wheelchairs prescribed for each 
diagnosis.  * denotes statistical significance at p<0.05 
 
When comparing the type of manual wheelchair issued, ultralight wheelchairs were the most 
common type of wheelchair issued to individuals with a SCI (Table 20).  For this same group, a 
depot wheelchair was the least frequently prescribed type of manual wheelchair.  On the other 
hand, ultralight wheelchairs were the least frequently prescribed wheelchairs to individuals with 
MS, with only 14.0% of all wheelchairs issued being ultralight.  Individuals with MS were more 
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likely to receive a lightweight wheelchair or a depot wheelchair.  In fact, 39.2 individuals with 
MS who received manual wheelchairs were issued depot chairs. 
 
Table 20 Distribution of four classes of manual wheelchairs issued to SCI and MS groups 
SCI MS Type 
Manual 
Wheelchair N % N % 
M1 
 
101 25.6 239 39.2 
M2 
 
126 32.0 285 46.8 
M3 
 
167 42.4 85 14.0 
Note:  Percentages given as percent of total number of manual wheelchairs issued for each 
diagnosis  
 
For individuals in the MS group, scooters were the most common type of powered mobility 
device prescribed (Table 21).  For individuals in the SCI group, however, a customized power 
wheelchair was the most common type of powered mobility issued.  On the other hand, only 
15.5% of the individuals with MS were issued a customized power wheelchair.   
 
 
Table 21. Compares the distribution of powered mobility in the two groups 
SCI MS Type 
Powered 
Mobility N % N % 
S1 51 12.8 294 39.0 
P1 126 31.7 189 25.1 
P2 76 19.1 154 20.4 
P3 144 36.3 117 15.5 
Note:  Percentages given as percent of total number of powered mobility issued to individuals 
for each diagnosis.  
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 4.5.DISCUSSION 
 
To the best of our knowledge, this is the first study to compare assistive technology prescription 
between individuals with MS and individuals with SCI.  This is an important area of 
investigation, given the satisfaction with AT between these two groups is so different (Cook et 
al, 1981; Scherer and Cushman, 2000; Perks et al, 1997).  For an individual with mobility 
impairments, AT can greatly affect their ability to participate in activities of daily living, and 
ultimately their quality of life.  A better understanding of the AT distribution and prescription 
may provide valuable insight as to why quality of life scores are so different between individuals 
with MS and individuals with SCI. 
 
4.5.1. Specific Aim 1: Demographic characteristics 
Based on the fact that there were no significant differences in the demographic characteristics of 
the group of data entries that were eliminated from the analysis and those included in the 
analysis, it is likely there was no selection bias based on data entry.   
 
According to Hubbard (2004), the average veteran receiving a wheelchair from the VA is a 
white, 69 year old male with chronic obstructive pulmonary disorder/ congestive heart failure 
(COPD/CHF).  Individuals with MS and SCI made up 3-4% and 6-8% of the total population of 
veterans receiving wheelchairs in the database, respectively (Hubbard, 2004).  According to our 
study, the average age of individuals with MS and SCI was statistically significantly different.  
However, because the difference in the mean ages and standard deviations was not more than 
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three years, this difference is not clinically significant.  Furthermore, there was no clinically 
significant difference in the mean ages of our samples and that of the general population of 
veterans receiving wheelchairs, which is approximately 55-56 years old (Hubbard, 2004).  The 
average age of an individual with a SCI is 31 years old and the average age of diagnosis of MS is 
37 years old.  
 
Our gender distributions are consistent with the overall distribution of US veterans, since the 
majority (95.2%) is male (http://www.cacvso.org/641,4,Slide 4).  Among the general population, 
the ratio of males to females with SCI is 4:1 (http://www.emedicine.com/pmr/topic182.htm ).  
However, in the general population, female individuals with MS outnumber male individuals 
with MS by 2.6:1 (http://health.yahoo.com/health/ceters/women/_19238199.html).  This may 
help explain why males with MS made up approximately 10% less of the population when 
compared to males with SCI. 
 
4.5.2. Specific Aim 2:  Comparison of devices 
Chi Squared analysis revealed that there was a significant difference in the general types of 
wheeled mobility (manual wheelchairs, power wheelchairs and scooters) issued to individuals in 
the two groups.  While there was approximately equal number of manual and power wheelchairs 
issued to individuals with a SCI, manual wheelchairs were the most common category of 
wheeled mobility issued to individuals with MS.  A recent study conducted in our laboratory 
investigated the efficacy of manual wheelchair propulsion in individuals with MS (n=15) who 
use a manual wheelchair as their primary means of mobility (Fay et al, 2004).  This study found 
that individuals with MS were unable to maintain a functional speed of wheelchair propulsion 
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when compared to control counterparts.  Kinetic analysis revealed that with each propulsive 
stroke of the wheelchair, individuals with MS imparted a force in the opposite direction of 
forward propulsion, essentially working against themselves every time they pushed the chair.  
This would lead to increased energy expenditure during wheelchair propulsion.  This is 
especially significant in this population, for whom fatigue is a major limiting factor (Krupp et al, 
1988).  It is therefore possible that many individuals with MS are being issued manual 
wheelchairs, even though it is not a functional means of mobility.  This study is limited by the 
fact that the database provides no information regarding disease progression for the individuals 
with MS.  It is a well-known fact that symptom presentation, and consequently, mobility 
limitations are extremely varied among different individuals with multiple sclerosis.  
Furthermore, this study is limited by the fact that it only considers two years of data.  Future 
studies should compare the differences in mobility device prescription between the two groups 
over an extended period of time.     
 
When we considered the individual types of manual wheelchairs, individuals with SCI were most 
likely to receive an ultralight wheelchair.  On the other hand, only 14% of individuals with MS 
who were issued a manual wheelchair received an ultralight chair.  Research has shown that 
ultralight wheelchairs are the best quality of wheelchair in terms of cost effectiveness and strain 
on the upper extremity of the user.  Specifically, although ultralight wheelchairs are the most 
expensive type of manual wheelchairs,  they have been shown to have higher number of 
wheelchair propulsion cycles per dollar than either depot or lightweight chairs (Fitzgerald et al, 
2001), and last 13.2 times longer than depot wheelchairs (Cooper et al, 1996).  Furthermore, 
ultralight and lightweight wheelchairs tend to experience repairable component failures, as 
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compared to depot wheelchairs, which tend to experience frame failures (Cooper et al, 1996).  
These wheelchairs also offer the adjustability needed to minimize the risk for upper extremity 
injury in individuals who rely on a manual wheelchair as their primary means of mobility.   
Boninger et al, (2002) showed that optimal horizontal and vertical positioning of the wheelchair 
axle decreases the forces imposed on the upper extremities during wheelchair propulsion.  
Therefore, the dichotomy in the types of manual wheelchairs issued to individuals with SCI and 
individuals with MS is important.  It is possible that individuals with MS are issued a poorer 
quality (heavier and less adjustable) of manual wheelchair because clinicians anticipate the 
progression of this dynamic disease.  Clinicians may view the use of a manual wheelchair as an 
intermediate step in the progression to an increased reliance on AT for mobility.  With this in 
mind, it is not surprising that a majority of individuals with MS state that their manual 
wheelchair does not meet their mobility needs (Perks et al, 1997).  It is also possible that, since 
many individuals obtain prescriptions for a manual wheelchair as a means to alleviate some of 
the daily fatigue, they don’t use the wheelchair as their primary means of mobility, and are 
therefore issued a lower quality of wheelchair.  Ironically, this may lead to an increase in the 
fatigue symptoms they are attempting to overcome, since depot and lightweight chairs are 
heavier than ultralight chairs, and therefore, would require an increased effort and energy 
expenditure.   
 
Our results revealed that individuals with MS are also less likely than individuals with SCI to 
receive a better quality of power wheelchair.  While individuals with SCI were most likely to 
receive a customized power wheelchair, individuals with MS were most likely to receive a 
scooter.  It can be argued that scooters are perceived as less of a symbol of disability when 
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compared to standard power wheelchairs.  Because of the unpredictable course of MS, it may be 
more difficult for individuals with MS to accept their increased reliance on AT for daily 
mobility.  They may view transitioning as a sign of ‘giving up’.  A scooter may offer a means to 
alleviate fatigue symptoms resulting from ambulation, without the self-perception of increased 
disability.  The psychosocial impact of accepting a transition in the primary means of mobility, 
particularly in individuals with MS, may provide very useful information for the wheelchair 
selection process.   
 
This study is limited by the fact that the NPPD does not provide information about the 
individual’s physical capabilities or functional impairments, therefore making it difficult to 
appraise the efficacy of device prescription in these populations.  In the general population, fifty-
two percent of individuals with a spinal cord injury (SCI) are considered paraplegic and 47% 
quadriplegic (http://www.sci-info-pages.com/facts.html).  However, in the NPPD database for 
2000 and 2001, once all the missing data were filtered, only 90 individuals with tetraplegic SCI 
remained in the analysis, indicating that we likely did not capture all veterans with tetraplegic 
SCI.  It is possible that clinicians coded veterans with tetraplegic SCI as another primary 
diagnosis besides definitive SCI, such as “quadriplegia or quadriparesis”.  This diagnosis was not 
included into the analysis, since it is possible that quadriplegia resulted from another pathology 
besides traumatic SCI, like MS.  Along these lines, it is more likely that tetraplegic SCI is 
accompanied with other secondary diagnosis, such as respiratory problems, which may have 
been used as the primary diagnosis for the clinican imputing the patient information.  Therefore, 
there may be some discrepancies in the classification of SCI when clinicians are inputting the 
primary diagnosis into the database.  The under-representation of veterans with tetraplegic SCI is 
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likely to have led to an underestimate of the number of power wheelchairs that were issued to 
veterans with SCI.  This would further widen the gap between the general types of wheeled 
mobility device (manual wheelchair, power wheelchair or scooter) issued to veterans with the 
two diagnosis. This study reveals that there exists a need for future reliability studies in ICD-9 
coding as it relates to wheelchair prescription within the VA.          
 
Finally, these results are specific to a veteran population with SCI and MS, and, because of 
differences in funding policies and patient demographics, are not generalizeable to the general 
SCI and MS populations.  A previous study has shown that individuals who have public 
insurance, such as Medicare and Medicaid, receive a lower quality of wheelchair when compared 
to individuals who have private insurance (Hunt et al, 2004).  The type of insurance confounder 
was removed from this study since all veterans received their assistive technology from the 
VHA.  However, it is likely that veterans receive a higher overall quality of wheelchair than 
individuals in the general population, especially those with public insurance, because of the 
increased purchase flexibility of the VA.  This is not the case when comparing the type of 
wheelchairs issued among veterans within the VA system, and individuals receiving their 
wheelchair from a Model Spinal Cord Injury Systems (MSCIS).  According to Hunt et al, (2004), 
97% of all the manual wheelchairs issued were ultralight.    
 
Along these lines, the quality of wheelchair issued is dependent on the facility in which the 
individual is being issued their new device.  Ideally, a wheelchair will be prescribed by a team of 
the consumer and rehabilitation professionals working together, such as would be found in an 
MSCIS setting (Hunt et al, 2004).  Such rehabilitation professionals include a physiatrist, a 
 108
physical or occupational therapist, and a rehabilitation engineer/ assistive technology specialist.  
Because of the acute nature of a SCI, individuals are more likely to receive a prescription for 
their new mobility device though a team as described.   On the other hand, because MS is a 
chronic, progressive disease, symptoms often have a slow onset, and, because of this, individuals 
may not have the same access to assistive technology specialists for their wheelchair 
prescription.  None-the-less, the benefits to be gained through the use of the most appropriate 
wheeled mobility apply to all individuals, regardless of disability.  
 
4.6.CONCLUSIONS 
 
Our study reveals that there is a disparity in the types of wheelchairs distributed to veterans with 
a SCI and MS.   Individuals with MS are less likely to receive ultralight wheelchairs when they 
are issued a manual wheelchair, and, when considering powered mobility, they are less likely to 
receive programmable, customizable power wheelchairs.  Instead, individuals with MS are most 
likely to receive a scooter. 
 
Based on these findings, effective solutions for optimizing the provision of AT devices among 
veterans with MS should be further investigated.  Future studies should seek to identify standards 
of care for issuing mobility devices to this population of individuals, with a complicated and 
unpredictable clinical course.     
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5. Proposal of:  THE EFFECT OF EARLY MOBILITY DEVICE INTERVENTION ON 
QUALITY OF LIFE AND PARTICIPATION IN INDIVIDUALS WITH MULTIPLE 
SLCEROSIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL 
 
 
 
5.1.INTRODUCTION 
 
We propose that, because of a lack of research in the area of mobility device prescription for 
individuals with MS, clinicians and wheeled mobility users themselves often have a difficult 
time knowing if and when is the best time to switch to a new mobility device.  Furthermore, 
when the decision to switch has been made, mobility device selection is difficult.  Currently 
published evidence supporting the importance of research in the area of mobility device delivery 
for individuals with multiple sclerosis has been cited throughout this document.   
 
Through a series of 3 studies considering:  1.  the characteristics of ambulatory individuals with 
MS who are about to transition to a new form of wheeled mobility, 2.  muscle strength, muscle 
fatigue and quality of life changes that accompany a transition in primary means of mobility for 
individuals with MS and 3.  the type of wheeled mobility devices commonly issued to veterans 
with MS, we have demonstrated that individuals with MS are already ambulating at non-
functional ambulation speeds, demonstrating sedentary levels of physical activity, and have 
compromised levels of quality of life and participation in daily activities at the time that they 
decide to transition to wheeled mobility.  We also found in a pilot study that the expected 
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declines in strength and muscle fatigue may not necessarily occur after this transition.   Finally, 
once a transition to an increased reliance on mobility device is made, veterans with MS seem to 
receive an inferior quality wheelchair when compared to veterans with a spinal cord injury.  
Taken together, we hypothesize that if a transition to wheeled mobility is made at an earlier stage 
in their disease progression, and if the wheelchair issued is prescribed to specifically match the 
needs of the user, individuals with MS will experience an improvement quality of life and 
participation.   
 
5.2.Work Completed to Date/ Continuing Work 
In order to provide more conclusive preliminary evidence of a need for an earlier transition in 
persons with MS, the two projects entitled “Correlates of ambulatory ability in persons with 
multiple sclerosis who are about to transition to a new primary means of mobility” and 
“Preliminary evidence of a need for an earlier transition in ambulatory individuals with multiple 
sclerosis: a methodological report” will be continued with protocol changes.  The protocol 
changes will be geared to address recruitment difficulties encountered, and to implement 
recommendations for improving chances for increased subject participation.   
 
The overall study design will follow that described in the methodological report, and testing will 
take place over 3 visits (V1-V3).  Participants will continue to be recruited through the Center 
for Assistive Technology (CAT) of the University of Pittsburgh.  A project co-investigator will 
approach clients of the CAT who have demonstrated an interest in participating in research 
studies.  The co-investigator will explain the testing procedure, and will consent the client, if 
they agree to participation.  As described in chapter 3, all individuals with a chronic, progressive 
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disorder (including all those diagnoses leading to a decline in mobility status, and excluding 
those resulting from cardiac conditions, orthopedic, or other conditions which would preclude 
strength testing) who have a referral for a new form of wheeled mobility will be included.  Even 
though we will no longer include the strength-testing portion of the protocol with the extension 
of this study, we will include the individuals with the same inclusion and exclusion criteria, so 
that the data can be pooled.  Transitions considered will include ambulation to manual 
wheelchair, ambulation to power wheelchair/ scooter, or manual wheelchair to power 
wheelchair/scooter.  In addition, individuals transitioning from ambulation to the use of a power 
assist wheelchair or from a manual wheelchair to a power assist wheelchair will be included.  We 
have decided to include this type of mobility device transition since clinical observation has 
revealed that individuals with MS with mobility impairments are increasingly transitioning to the 
use of power-assisted wheelchairs as their new primary means of mobility.  Other inclusion/ 
exclusion criteria as previously described will remain the same.   
 
V1 testing will take place either at the CAT, on the same day of wheelchair prescription, or at the 
participant’s home, within two weeks of wheeled mobility prescription.  V2 testing will take 
place either at the CAT, on the day of wheelchair delivery, or again, at the participant’s home, 
within two weeks of device delivery.  Finally, V3 testing will take place at the participant’s 
home, at a time interval equal to that between V1 and V2, +/- 2 weeks.   
 
The testing protocol will be shortened so that it may easily be conducted at the CAT or at the 
participant’s home.  Therefore, the protocol will consist of functional testing, questionnaires and 
mobility monitoring.  All testing should take approximately one hour.   
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 Functional testing will include the fast trial timed 8-meter walk test and the normal walking 
speed 8-meter walk test.  The functional wheelchair propulsion trial will be eliminated from the 
protocol since it will be difficult to conduct in many subjects’ homes.  If the subject does not 
have an area of the home in which they will be able to safely perform the ambulation testing 
trials, this portion of the testing will be eliminated.  In addition to recording the type of mobility 
device used to complete the trial, the investigator will record the type of surface in which the trial 
was completed, and the surface will be the same over the three visits, when possible.     
 
Questionnaires to be completed by the participants will include an intake questionnaire to obtain 
subject demographics and information about their diagnosis, the SF-36, the CHART and the 
MFIS.  As a part of the intake questionnaire, participants will continue to be asked if they had 
fallen in the last month, and if so, how many times.  In addition, they will be asked to describe 
what they believe to be the primary reason for their fall(s), if any.   
 
Using a pedometer and a datalogger, both ambulation and wheeled mobility device use will 
continue to be monitored in the week following research testing.   
 
5.3. Randomized Controlled Clinical Trial 
The purpose of this investigation will be to test the effect of an early mobility device intervention 
in persons with MS on quality of life measures.  We hypothesize that a transition to a powered 
mobility device at a level when functional ambulation is first compromised and when self-
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reported fatigue limits daily participation in persons with MS will lead to an increased quality of 
life.  
 
5.3.1. Study design 
We will recruit 40 subjects in the Pittsburgh area.    
5.3.2.  Inclusion Criteria 
• MS as diagnosed by the McDonald criteria (McDonald et al, 2001) 
• Individuals who ambulate slower than 0.8 m/sec as determined by the timed 25 foot walk 
test (T25FW) 
• Individuals who do not already have a powered mobility device 
• Individuals who score of 12 or below on the Modified Fatigue Impact Scale (MFIS) 
• Must have some means of transporting (f.g. wheelchair lift) and disassembling powered 
mobility device 
• Between the ages of 18 and 65 years 
5.3.3. Exclusion Criteria 
• MS exacerbation within 3 months prior to visit 1  
• Any other diagnosis besides MS that is responsible for a decline in their functional 
mobility 
 
The T25FW and the MFIS will be used as inclusion criteria since we have previously shown that 
they relate to average number of daily steps and daily participation, respectively.  For the 
T25FW, 0.8m/sec was used as a cut-off since it has been previously shown that functional 
walking speed is 1.2m/sec- the time needed to cross a street intersection (Lerner-Frankiel et al, 
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1986), and this value is expected to decrease by approximately 30-34% with age (Samson et al, 
2001). An MFIS score of 12 was used since the mean MFIS score of the individuals who 
participated in our previous study (Chapter 2) was 13 +/-3.  We hypothesize that at the time these 
individuals were included into the previous study, their fatigue was already at a level that 
significantly limited their daily participation.  Since the EI group will receive a mobility device 
intervention at a time earlier than would typically occur, and therefore, are likely to be without 
home and vehicle wheelchair modifications, an inclusion criteria was established that only those 
individuals with a means of transporting or disassembling their new powered mobility device 
will be included.  This will include having a car or van lift, someone available who is able to 
help disassemble the wheelchair and put it into the vehicle, and/ or access to public 
transportation.  This will preclude the likelihood that participants do not use their new mobility 
device based solely on the fact that they do not have a means to functionally use the new 
wheelchair.  In addition, no participant will be included in the study if they have had an MS 
exacerbation within the last 3 months.  This is to minimize non-representative baseline 
measurements as a result of a recent flare-up in symptoms.  Along these lines, if a participant has 
an exacerbation while included in the study, the exacerbation will be noted in the chart, however, 
this individual will continue in their participation.  If the participant’s data appears to be an 
outlier, exacerbation symptoms will be treated as a confounder.   
 
We will use a randomized controlled clinical trial for this study.  Ambulatory individuals with 
MS will be recruited at the physician’s office by a clinical coordinator, who will consent subjects 
into the study, with their approval.  Subjects will be screened for eligibility, and the clinical 
coordinator will ask them to perform the T25FW and to complete the MFIS.  We have 
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previously shown that the T25FW and the MFIS are quick and easy-to-use surrogate tools that 
may be used to estimate daily physical activity and participation in persons with MS (Please see 
Chapter 2).  Therefore, we will use these tools as benchmarks for when a transition to the use of 
a wheeled mobility device may be indicated.  Those individuals meeting the inclusion/ exclusion 
will be randomized into one of two groups, the early mobility intervention group (EMI) and the 
normal mobility intervention group (NMI).    Randomization will be carried out using computer-
generated numbers to assign each subject to one of the two groups.  Only the clinical coordinator 
will know to which of the two groups the subject was assigned.  The investigators obtaining 
outcome measurements will not know to which intervention group the subject was assigned.   
 
Individuals randomized into the NMI group will receive a normal standard of care, in which the 
physician will determine if and when a mobility device is indicated.  The EMI intervention group 
will be referred to an assistive technology specialist to receive a new powered mobility device 
(Figure 1).  All testing will either take place at the Center for Assistive Technology (CAT), or at 
the participant’s home.  Participants will complete testing over three visits:  
• Baseline testing (upon receipt of new wheeled mobility device for EMI participants, and 
upon inclusion into the study for NMI participants),  
• Visit 2- two months after baseline testing, and  
• Visit 3- one year after baseline testing.   
 
Two months was chosen as the time frame for the second visit testing since it will provide 
information about how well the individuals in the EMI group are adjusting to the use of their 
new wheelchair.  One year was chosen as the time frame for the third visit since it is expected 
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that individuals will be accustomed to using the new wheeled mobility device, and will have a 
regular pattern of use.   
 
For each visit, testing will be completed as follows:   
1. Functional ambulation 
2. Questionnaires 
3. Mobility monitoring 
 
5.3.4. Special Considerations 
Certain considerations will be taken in order to control for external variability that may 
contribute to measurement error.  These are: 
• When possible (ie. testing performed at the CAT), room temperature will be constant 
throughout testing of all subjects (i.e. 70°F ±  2°F) 
• Examinations will be performed at the same time of day for all subjects (between 10AM 
and 12PM) 
• Subjects will be asked to avoid strenuous activity the day of testing 
 
5.3.5. Outcome Measurements 
5.3.5.1. Functional ambulation 
The timed 25-foot walk (T25FW) will be used as a clinical measure of ambulatory impairment.  
The T25FW or similar tests have been used in several studies looking at gait impairment in MS 
(Schwid et al, 1997), and has been shown to provide meaningful information about impairment 
in this population (Schwid et al, 1997).  Subjects will ambulate a straight 25-foot, level surface 
course as fast as they are able, using whatever type of ambulatory aid they feel is necessary (the 
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same ambulation aid will be used during each visit).  Subjects will be encouraged to walk with 
the least amount of assistance possible.  The type of ambulation aid will be recorded, and will be 
the same for each visit testing.  Subjects will wear a pedometer during this portion of the testing 
(see mobility monitoring below).   
 
5.3.5.2. Questionnaires 
Fatigue:  The Modified Fatigue Impact Scale (MFIS) (Fisk, 1994a; Fisk, 1994b) is a shortened 
version of the 40-item Fatigue Impact Scale (FIS) questionnaire designed to assess the problems 
in patients’ quality of life that they attribute to their symptoms of fatigue.  Therefore, it measures 
fatigue severity more directly than the Fatigue Severity Scale (Krupp, et al, 1989), another 
commonly studied questionnaire we considered.  The FIS has separate subscales in which 
patients rate the impact of fatigue on physical (10 items), cognitive (10 items), and psychosocial 
function (20 items).  In the initial validation studies, FIS subscales had good internal consistency, 
and each subscale demonstrated worse fatigue in MS and CFS patients than hypertensive 
controls (Fisk et al, 1994b).  There was no association between FIS and EDSS scores, suggesting 
that the FIS was measuring fatigue rather than neurologic impairment/disability.  A shortened 
version of the FIS, the MFIS, (eliminating 19 redundant items) has been incorporated into the 
MS Quality of Life Inventory, recommended for monitoring in clinical and research settings by 
the Consortium of MS Centers and the National MS Society.   
 
Quality of Life:  All subjects will assess their quality of life using the SF-36 Health Survey, 
widely acknowledge as the “Gold Standard” for generic measure of health status (Freeman et al, 
2000)(Appendix 4).  This survey measures the functional effect of an illness as perceived by the 
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patient, and is one of the most commonly used measures of quality of life (Nortvedt et al, 1999).  
The key variables of the SF-36 to measure change in health-related QoL over time  will be those 
measuring physical components (physical function (PF), social functioning (SF), role physical 
(RP), bodily pain (BP), general health (GH), and the physical composite score (PCS).  We have 
shown that, when compared to the general population, these domains tend to be lower in 
individuals with MS who are about to transition in their primary means of mobility (Chapter 2).  
The internal consistency, reliability, and validity of this survey as a measure of health status in 
multiple sclerosis have been confirmed (Freeman et al, 2000; Ware et al, 1993).  Furthermore, 
the SF-36 has been shown to be sensitive to early changes in MS (Canadian Burden of Illness), 
and was predictive of EDSS scores after one-year (Nortvedt, MW et al, 2000).  Therefore, this 
outcome measure will provide valuable information regarding perceived health status by the 
subject.  However, limitations, such as floor and ceiling effects, as well as poor responsiveness 
for change, have been demonstrated in individuals with MS (Freeman et al, 2000).  For this 
reason, it has been recommended that this tool be used in conjunction with other measures 
(Freeman et al, 2000). 
 
Participation:  The Craig Handicap Assessment and Reporting Technique (CHART) is a 27-
question outcome tool used for measuring quality of life in terms of participation in everyday 
activities as well as in social activities (Whiteneck et al, 1992).  The key variables of the CHART 
to be considered are the mobility and the occupation summary scores.  These summary scores 
will be used to measure change in daily participation over time, since, when compared to the 
general population, these domains measuring physical functioning have been shown to be lower 
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in individuals with MS who are about to transition in their primary means of mobility (Chapter 
2).  
 
Impact of Assistive Device:  The benefits of an assistive technology device may only be as great 
as the satisfaction and acceptance of the device by the individual.  With this in mind, the 
Psychosocial Impact of Assistive Device Scale (PIADS)(Day & Jutai, 1996) will be administered 
to the subjects one week after AT delivery, and then again at T3.  The PIADS is designed to 
measure the impact of the assistive device within three domains including: competence, 
adaptability, and self-esteem (Appendix 6).  The reliability coefficient and the split-half 
reliability of the PIADS are high (Cronbach’s alpha= .95 and Guttman split-half= .89, 
respectively)(Day and Jutai, 1996). An extra question will be added asking subjects to estimate 
average daily use (in hours) of the newly acquired mobility device. 
 
 
5.3.5.3. Mobility Monitoring 
Since we have previously shown that the effect of a transition to the use of wheeled mobility on 
quality of life seems to be dependent on amount of device use (see Chapter 3), we will monitor 
the EMI group’s ambulation and wheeled mobility device use for one week after each testing 
session.  We will measure the amount of ambulation and mobility device use at each time point. 
The key variable for both of these measures will be distance traveled in steps/day and in meters 
per week, respectively. 
 
After completing all testing, each subject will be given a pedometer. The subjects will be asked 
to record the pedometer value each night. The pedometer will provide the distance each subject 
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walks in a day.  Pedometers have been shown to be a valid and cost effective means of 
monitoring physical activity (Tudor-Locke et al, 2002).  Because readings may not always be 
accurate in people with disabilities (Macko et al, 2002), subjects will wear the pedometer during 
the T25FW.  If inaccurate readings (greater than 10% error) are seen we will ask the subject to 
repeat the T25FW two additional times and we will create a correction factor to be used when 
calculating distance traveled for the following week. If needed, this correction factor will be 
calculated at each visit. Although there may be error in this measure with abnormal gait, this is 
the most cost effective and least invasive method of determining the amount walked. After one 
week, the participant will be asked to mail the pedometer to the Human Engineering Research 
Laboratories (HERL). If the subjects do not wear the pedometer for a day, that day will not be 
included in the analysis and we will average other days to replace the missing data point and 
arrive at a total distance traveled.  
 
In addition, we will mount a data logger (Spaeth et al, 2000) on the wheelchair or scooter of the 
participants in the EMI group, and any wheeled mobility device the participants in the NMI 
group may receive during their inclusion in the study. The data logger provides total distance 
traveled in the wheelchair as well as when the distance is traveled. We will phone subjects as 
described above, and at the end of one week, the subjects will mail the data logger and the 
pedometer back to HERL. 
 
5.3.6. Data analysis 
5.3.6.1. Power Calculations 
Based on means and standard deviations of existing research for the SF-36 (Trefler et al, 2004), 
and unpublished research completed at our laboratory on changes in social participation as 
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measured by the CHART, we will have 80% power at an alpha of 0.05 with 20 subjects in each 
group.  We expect to see large increases (change in score by 15 points) in the SF-36 over time.   
5.3.7. Threats to the Study 
• Results may be affected by acute exacerbations, changes in pharmacological 
interventions, or changes in physical activity level during the study period.  It is likely 
these will be randomly distributed among the two groups, such that they do not 
drastically affect results.  During each visit, we will record medications used and ask 
subjects if they have experienced an MS exacerbation since the last visit (defined as a 
new or worsening symptom lasting for at least 48 hours in the absence of fever or 
infectious illness).  Any exacerbation will be recorded.  Analysis will be performed with 
and without patients with a change in exacerbation or a change in medication in order to 
determine whether they significantly alter results.      
• There is likely to be variability in daily amount of wheelchair and scooter device usage.  
This is true both because many of the individuals who participate in the study may not 
feel they need a new mobility device, and since individuals in the EMI group who receive 
a powered mobility device will probably not have home and vehicle modifications.  We 
will attempt to control for this by quantifying the average daily usage of the newly 
acquired mobility device through use of the data logger and a pedometer.  If there is a 
substantial variability between subjects, an ANCOVA will be calculated, using wheeled 
mobility device distance traveled per day as a covariate.  In addition, we will collect 
information on satisfaction with and acceptance of the device through the PIADS.  
• Heterogeneity in the study population may interfere with evaluations.   While individuals 
with MS often present with a wide range of symptoms, increasing between-subject 
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variability, our ultimate goal is to quantify the effect of early mobility device intervention 
on quality of life and daily participation.  Therefore, we chose to keep the eligibility 
criteria fairly broad, to observe the full spectrum of changes and provide highly 
generalizable results.   
• Patients assigned to the NMI group may all receive a new wheelchair, and may get their 
wheelchairs sooner because of participation in the study.  Participants will be blinded as 
to the two different groups, in addition to the evaluator being blinded.   
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 Figure 11. Project Schematic 
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6.  CONCLUSIONS 
 
 
The Matching Person and Technology Model is composed of three primary components:  1) the 
technology, 2) the milieu or the environment in which the user will interact with the technology 
and 3) the technology user him/herself.  The effectiveness of the technology is only as good as 
the fit between the user and the technology to achieve the desired goal (Scherer, 1998).  In all too 
many cases, where these three components don’t quite fit, the wheelchair user experiences 
decreased satisfaction, and may eventually abandon the new chair.  Such a “lack of fit” may 
result from inappropriate technology prescription, poor timing to introduce the intervention, or 
from the individual being intimidated by certain unknowns involved in acquiring the new device, 
for example. 
 
Gaps in the adequacy of wheeled mobility device prescription may be attributed to the point of 
view from which rehabilitation professionals and the users themselves often approach disability.  
Working from a medicalized perception of disability (The Individual Model of Disability), the 
cause of the ‘problem’ is within the individual themself; a person with a mobility impairment is 
disabled because they are unable to walk.  Therefore, the main purpose of the intervention, in 
this case, the wheelchair, is to cure the disability, and not to ameliorate social conditions or 
circumstances.  It is inevitable that this will lead to a decreased satisfaction with the assistive 
technology, since the intervention is not purposed to meet the outcome needs of the user.  It is 
our belief that the wheelchair prescription process for individuals with MS commonly occurs 
from the Individual Model perspective. 
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Unlike most individuals with a SCI who report satisfaction with their assistive technologies 
(Scherer and Cushman, 2000), a majority of the individuals with MS who use a manual 
wheelchair feel their current wheelchair does not meet their mobility needs (Perks et al, 1997).  
With this in mind, the association between mobility and quality of life (Aronson et al, 1997) may 
help explain decreased reported health related quality of life scores between individuals with MS 
and both the general population (Nortvedt et al, 1999) and those with other chronic disabilities 
(Lankhorst et al, 1996)  
 
The above findings raise the following questions: Is the decreased satisfaction with AT common 
to individuals with MS a result of being issued a mobility device of lower quality?  Or is it a 
result of a decreased ability to define when is the best time to transition and what indicators 
should be used to determine when an individual with MS is in need of a new wheelchair?  And 
finally, is the decreased satisfaction with mobility device use a result of secondary effects of 
using a wheelchair, such as increased weakness and deconditioning, and consequent decreased 
functioning?  These are all questions we attempted to address in this work.  Specifically, we 
considered the technology (wheelchair), the user, and the interaction between the two.   
 
6.1. The Technology 
The first step in our investigation considered the quality of the technology (wheelchair) being 
issued, and whether a disparity exists in wheelchair types that are issued to veterans with MS and 
veterans with SCI.  We hypothesized that veterans with MS are being issued manual and power 
wheelchairs that are of a lower quality when compared to veterans with SCI.  To test this 
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 hypothesis, we analyzed two consecutive years of data from the Veterans Health Administration 
National Prosthetics Patient Database (NPPD), which contains information of all orthotic, 
prosthetic, and sensory devices issued to veterans.  From this database, were able to isolate a 
group of veterans with MS and a group of veterans with a SCI who had received a wheelchair or 
scooter in 2000 and 2001.  By linking the NPPD with the National Patient Care Database, we 
were able to obtain demographic information about these two groups of veterans being issued a 
new mobility device.   
 
We compared 791 veterans with a SCI with 1364 veterans with MS who received a manual 
wheelchair, a power wheelchair or a scooter.  The average age of veterans with MS was 55.3 +/- 
12.0 years and the average age of veterans with a SCI was 52.8 +/- 14.0 years.  The majority of 
veterans, both with MS and a SCI, were white males.  While, because of our large sample size, 
there were statistically significant differences in the ages and races of the two groups, these 
differences were not clinically significant.  We did, however, find clinically significant results 
when comparing the type of mobility devices most commonly issued to veterans from each 
group.   
 
Overall, veterans with MS were significantly more likely to receive a scooter than veterans with 
SCI (21.6% and 6.4%, respectively), and less likely to receive a power wheelchair (33.7% and 
43.7%, respectively).  There was also a statistically significant difference in the types of manual 
and power wheelchairs issued.  Only 14% of veterans with MS were issued ultralight 
wheelchairs, as compared to 42.4% of veterans with a SCI.  Similarly, 15.5% veterans with MS 
and 36.3% veterans with a SCI received customized, programmable power wheelchairs. 
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A suboptimal wheelchair may result in a major disturbance in the individual’s daily functioning.  
From our study, we found that the usability and cost-effectiveness of wheelchairs issued to 
veterans with MS need improvement.  The types of manual wheelchairs commonly issued to 
veterans with MS do not allow them to adjust the set-up, leading to an increased likelihood for 
upper extremity injury and increased energy expenditure.  Similarly, the types of powered 
mobility commonly issued to veterans with MS do not allow for customizability to meet their 
individual needs.  Taken together, it can be argued that the mobility technology issued is not 
meeting the intended goal of allowing the individual to most effectively function in their daily 
environment.   
 
With the medicalization of disability, individuals with SCI demonstrate clinically measurable 
mobility limitations, where, clearly, assistive technology is a very appropriate intervention.  On 
the other hand, individuals with MS may oftentimes not be considered as “disabled,” since 
standard tests of strength, spasticity, and sensation are not sensitive enough to detect mobility 
deficits in this population (Ambrosio et al, 2002)  Therefore, the need for assistive technology 
may not be as readily identified until later in the disease progression.   
 
6.2. The User 
The purpose of a wheelchair, as is true for any assistive technology device, is to “increase, 
maintain, or improve functional capabilities of individuals with disabilities.” (US Technology-
Related Assistance of Individuals with Disabilities Act of 1988).   Therefore, the received benefit 
of the wheelchair is only as effective as the extent to which it meets the needs of the individual 
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 and allows them to better function in their daily environment.  The need for mobility aid must be 
recognized early enough so that participation in activities and quality of life are not 
compromised.  The second project of this study aimed to describe the individual with MS who is 
about to transition in their primary means of mobility.  From this, we hoped to gain preliminary 
information about clinical indicators that can be used to identify a need for mobility device use.   
 
Specifically, we investigated walking ability and physical activity at home, while collecting 
information about their self-reported fatigue, participation in daily activities, and quality of life.  
To do this, we recruited seven individuals with MS who had a prescription for a new mobility 
device (manual wheelchair, power wheelchair or scooter), but who had not yet received their 
new device.  Each subject completed a timed 25 foot walk test (T25FW), where they were asked 
to ambulate 25 feet as fast as they were safely able, using whatever ambulation aid they felt was 
necessary.  They were also asked to complete a series of questionnaires including: the Short-
Form36 Quality of Life questionnaire (SF-36), the Craig Handicap Assessment Reporting 
Technique (CHART) to assess their daily participation in activities, and the Modified Fatigue 
Impact Scale (MFIS).  All the above testing took place at the Human Engineering Research 
Laboratories.  At the end of the testing protocol, subjects were given a pedometer to take home, 
and were asked to wear the pedometer all day, every day for one week, recording the pedometer 
reading each night before going to bed.  
 
The average time to complete the T25FW was 13.1 +/- 5.0 seconds (0.61m/sec) and they 
ambulated an average of 2,047 steps/day.  The T25FW correlated significantly with the average 
daily number of steps.  Individuals with MS scored considerably lower on all domains of the SF-
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 36 when compared to the general population, with exception of two domains which measured 
emotional and mental health.  In these two domains, they actually scored higher than published 
norms.  Similarly, for domains of the CHART primarily measuring physical functioning, 
subjects scored lower than norms published for the general US population, but only slightly 
lower when considering cognitive functioning.  Self-reported fatigue was not correlated with any 
of the quality of life variables; however, it was significantly negatively correlated with the 
mobility and the occupational participation scores of the CHART.   
 
Clinical observation reveals that individuals often fear a transition to wheeled mobility because 
they fear it will lead to increased deconditioning and consequent increased rate of functional 
decline.  However, from these results, we have found that individuals with MS who are waiting 
to transition to a new primary means of mobility may already be considered sedentary at the time 
of mobility device prescription.  The T25FW may be a quick and easy clinical tool for estimating 
physical activity in this population.  Furthermore, these individuals have generally lower quality 
of life scores and a decreased participation in daily activities, when compared to the general 
population.  Given the relationship in self-reported fatigue and participation, the MFIS may also 
be a valuable tool as a clinical indication of when fatigue is beginning to affect an individual’s 
ability to fully engage in everyday life activities. 
 
Issuing a wheelchair only at the point at which the individual is no longer physically capable of 
independent mobility also works under the Individual Model framework.  Under the Individual 
Model of disability, individuals with MS may oftentimes not  be considered “disabled” because 
standard tests of strength, spasticity, and sensation are not sensitive enough to detect mobility 
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 deficits.  Therefore, if they test “normal”, assistive technology is not indicated until later on in 
their disease progression.  On the other hand, for individuals with SCI, who demonstrate 
clinically measurable mobility limitations, clearly, assistive technology is an obviously 
appropriate intervention.   
 
This is flawed because, as seen from this study, at the time a need for mobility device 
intervention is identified, these individuals have already experienced a decrease in daily physical 
activity, and a consequent decrease in participation in life activities that may be a result of an 
increase in their self-reported fatigue.  Together, this may help explain the decreased quality of 
life scores seen in this population.   
 
6.3. The Technology/ User Interaction 
When considering the general population of individuals with mobility impairments, there is a 
relatively large body of research that investigates the technology and the user, when considered 
separately.  However, very little research exists that considers the interaction between the two.  
The purpose of the third and final project of this study was to investigate the effect of mobility 
device use on strength, fatigue, and quality of life, over time. 
 
Given the difficulties recruiting and retaining individuals with MS for a longitudinal study, this 
study considered all individuals with chronic disorders as they were transitioning in their primary 
means of mobility.  Any progression to an increased use of assistive technology (manual 
wheelchair to power wheelchair use, for example) for daily mobility was considered.   
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 Subjects completed testing over three visits.  The first occurred at or near the time when they 
received a prescription for a new wheeled mobility device (V1), the next at the time that they 
receive their new device (V2), and finally, after they had been using their new device over a time  
equivalent to the time between V1 and V2 (V3).  Eleven individuals completed and were 
included in the V1 data analysis, six in V2, and three in V3.   
 
For all three visits, ambulatory ability, physical activity, self-reported fatigue, social participation 
and quality of life were recorded as described in the second project.  In addition, the BioDex 
System 3 was used to test maximal muscle strength and muscle fatigue was measured for the 
knee extensors, knee flexors, ankle dorsiflexors, hip flexors, elbow flexors and elbow extensors.  
Electromyography was also performed to asses the muscle fatigue of the knee extensors, ankle 
dorsiflexors, elbow flexors and elbow extensors.   
 
Even with a modest sample size, we found a tendency that individuals retained functional 
ambulatory ability as well as muscle strength and endurance, while concomitantly experiencing 
improvements in psychosocial parameters that seemed to relate to the amount of new mobility 
device use.  Findings such as these may be helpful to individuals who are faced with mobility 
device intervention decisions, and may help alleviate common fears that an increased reliance on 
assistive technology will lead to an increased rate of disease progression.   
 
When considering wheelchair prescription, the medical model has failed individuals with MS.  
These individuals do not demonstrate the classic profile of an individual with mobility disability.  
Because of this, many individuals wait to transition to assistive mobility only at a point where 
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 they have a compromised participation in everyday activities and decreased levels of physical 
activity.  Furthermore, when the transition occurs, these individuals tend to receive lower end 
mobility aids when compared to individuals with SCI.  From our results, we have no indication if 
this trend in prescription is due to attitudes and beliefs of the health care provider, or whether 
from the individual themselves.  Clinical observation has shown that individuals with MS do 
have a tendency to request assistive technology that they view as less stigmatizing and disabling, 
such as scooters.  However, our final study has provided preliminary evidence to refute these 
misconceptions.  We are finding that wheelchair use, instead of being a disabler, facilitates 
increased quality of life scores, without resulting in significant decreases in ambulation and 
strength levels.   
 
6.4. Future Work 
Future studies should seek to further investigate other aspects of the Matching Person and 
Technology Model in individuals with MS, and specifically, the wheelchair prescription process.  
For example, it has been shown that individuals who live in wheelchair accessible homes tend to 
use their wheelchair more often (Hoenig et al, 2002).  With this in mind, and considering the 
potential impact of an appropriate environment on the level of satisfaction with assistive 
technology, investigating the extent to which individuals with MS are receiving appropriate 
home modifications for optimal use of their wheelchair is important.   
 
Another area that was not within the scope of this investigation, yet bears great influence on the 
appropriateness of mobility device prescription is the amount of consumer education/ training on 
the use of a wheelchair or scooter that is provided to individuals with MS.  Training and 
142 
 consumer education regarding wheelchair use is important given the importance of wheelchair 
propulsion techniques and set-up on the ability to effectively use a wheelchair (Boninger et al, 
2000).  Therefore, it is important to investigate the amount of training on the proper use of a 
wheelchair that individuals with MS receive.  Because MS is a dynamic, progressive disease, the 
introduction of a new mobility device may come slowly, and this may be at the expense of 
proper instruction on how to best use their new device within their environment.  
 
Based on the findings from these studies, it is our belief that individuals with MS would benefit 
from a consideration of a transition to a wheeled mobility device at an earlier stage in their 
disease progression, and from a higher quality of wheeled mobility.  The T25FW and the MFIS 
may be useful tools for clinicians to know when a change to wheeled mobility may be indicated.  
Furthermore, from a methodological perspective, given the difficulties with subject recruitment 
in this population, investigators should design research protocols that take into consideration 
barriers such as encountered in these studies.  Recommendations include the use of a full-time 
clinical coordinator to focus on subject recruitment, and a protocol designed to be conducted 
within the subject’s home to minimize the risk of subject testing cancellation.   
 
These studies, taken together, have shown that the Individual Model has failed to identify 
individuals who could benefit from mobility device.  We propose that wheelchair prescription 
from a Social Model of disability perspective would be able to sooner identify these individuals 
by a decreased functional mobility, decreased social participation and decreased quality of life 
scores.  The Social Model of disability, unlike the Individual Model, identifies the individual’s 
limitations as society’s failure to provide appropriate services and to ensure that individuals with 
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 disabilities are provided with the necessary provisions to integrate into their community.  
Therefore, a switch to wheelchair prescription, under the Social Model, has the potential to 
benefit individuals with MS.  It is our belief that drawing from a social model, where outcomes, 
and not physical disabilities, are of key interest would have two effects:  1) increased quality of 
the wheelchairs prescribed and 2) mobility device prescription when physical activity levels, 
participation and quality of life first begin to decline. 
 
In Chapter 5, we described our plans to continue with the longitudinal study (Chapter 3), with 
protocol modifications based on our own recommendations.  Furthermore, we outlined a 
randomized, controlled clinical trial, designed to test our hypothesis that an earlier transition to 
wheeled mobility in individuals with MS will lead to a decrease rate of decline in quality of life 
and daily participation.  Together, the studies we have conducted, are currently conducting, and 
plan to conduct, as outlined throughout this thesis, set up a framework for much needed research 
in the area of mobility device use in individuals with MS.  Finally, it is our hope that the results 
from these studies will be an impetus for continuing research in the area.  
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